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ABSTRACT
The work presented in this dissertation employs nanomaterials derived from a group of
uniform materials based on organic salts (GUMBOS) for selective chemotherapeutic applications.
GUMBOS, similar to ionic liquids, are organic salts consisting of a bulky cationic and anionic
moiety. In contrast to ionic liquids, these materials have melting points ranging from 25–250 °C,
making them solid phase at room temperature. Similar to ionic liquids, GUMBOS display tunable
properties, such as hydrophobicity and solubility, through counter ion variation. These tunable
properties provide a variety of applications for these GUMBOS, including selective
chemotherapeutics applications. The work in this dissertation evaluates the chemotherapeutic
behavior of a series of nanomaterials, i.e, nanoGUMBOS, derived from rhodamine dyes to
examine the role of both anion variation as well as cation structure on the therapeutic efficacy of
the nanoparticle. Firstly, the mechanism of selective toxicity of previously investigated rhodamine
6G (R6G) nanoGUMBOS was determined. Interestingly, these R6G nanoGUMBOS displayed
internalization via endocytosis in cancer cells while they lacked endocytic internalization in
normal cells. This variation in internalization pathways ultimately resulted in the observed
selective behavior of these R6G nanoGUMBOS. In my second project, the role of cyclodextrin
(CD) templating on the size and selective chemotherapeutic behavior of these R6G nanoGUMBOS
was evaluated. These CD-templated nanoGUMBOS displayed a remarkable two to three-fold
increase in toxicity with no effect on selectivity. In my latter two chapters, the therapeutic efficacy
of nanoGUMBOS derived from various rhodamine dyes is examined to assess the role of cation
structure on selective chemotherapeutic behavior. Intriguingly, a significant difference was found
in the selective behavior of GUMBOS derived from ester and carboxylic acid derivatives. In this
regard, nanoGUMBOS derived from ester derivatives displayed selective chemotherapeutics

xiii

toxicity similar to that of R6G nanoGUMBOS. In contrast, GUMBOS derived from carboxylic
acid rhodamines displayed non-selective behavior, suggesting that the selectivity was structure
dependent. Further examination of a triple nanoGUMBOS structure corroborated these results as
modification of the carboxylic acid structure led to complete selectivity of these nanoGUMBOS
under examined conditions. Moreover, these studies demonstrate the promising therapeutic
potential and advantages of rhodamine based nanoGUMBOS for selective chemotherapeutic
applications.

xiv

CHAPTER 1
INTRODUCTION
1.1. CHARACTERISTICS OF CANCER
As reported by the National Cancer Institute, despite the development of several treatment
methods, cancer remains the second leading cause of death in the United States in 2017.1-2 Cancer
is defined as the uncontrolled replication of cells that ultimately leads to formation of a tumor that
can damage the body’s healthy cells. These tumors are typically classified as either benign or
malignant.3-4 Benign tumors are a mass of cells that lack the ability to travel or metastasize to
neighboring tissue. In contrast, malignant tumors are a mass of cells that continuously grow and
travel to neighboring tissues resulting in disrupted oxygen and nutrient flow to the surrounding
normal tissues.5 These malignant tumors form as a result of genetic mutations within normal cells,
which ultimately leads to conversion of the normal to cancer cells through a phenomenon known
as oncogenesis.6 In the case of normal cells, replication can be controlled through a cellular defense
mechanism termed apoptosis. Apoptosis refers to programmed cell death to maintain proper
conditions of tissues and organs and eradicate the dysfunctional cells. In cancer cells, several
genetic mutations leads to formation of oncogenes that cause significant changes in the normal
cell processes.7-8 Specifically, oncogenes that inhibit apoptosis result in an imbalance between cell
growth and cell death; thus, leading to uncontrolled cell growth and eventual conversion of the
normal cell into an immortal cancer cell.9
This process of oncogenesis can be triggered by a variety of either genetic or
environmental/lifestyle factors. Genetic factors include inherited DNA mutations, hormone
imbalance and immune conditions. External/lifestyle factors include consumption of tobacco and
alcohol, diet, exposure to radiation, and environmental pollution. In this regard, the majority (9095%) of most cancer causes are attributed to environmental factors, while genetic factors only
1

correspond to about five to ten percent of these cases. Furthermore, the majority of these
environmental/lifestyle factors include tobacco consumption, diet and infections. Other
environmental factors such as stress, environmental pollutants and exposure to radiation only play
a minor role.10-11 High risk lifestyles and inherited genetic mutations can lead to the DNA
mutations that trigger oncogenesis and ultimately leading to the formation of a tumor. Moreover,
cancer caused by these environmental factors can be prevented through lifestyle modifications can
minimize exposure to these toxic substances. Furthermore despite several advancements in
detection techniques, due to their unique characteristics, some cancer are only detected after 10
years of exposure to the toxin that triggered oncogenesis.11
These unique characteristics of cancer cells that distinguish them from normal cells
develop from the physiological changes they undergo doing oncogenesis. In their studies, Hanahan
and Weinberg described these physiological changes as the eight hallmarks of cancer.12 Firstly,
the alteration during oncogenesis allows cancer cells to stimulate self-growth as a mechanism to
bypass the needs of a normal tissue for continual growth. This self-growth is stimulated by selfsecretion of growth hormones through autocrine signaling, permanent activation of pathways that
stimulate growth, destruction of negative feedback that prevents uncontrolled growth, and other
mechanisms of autocrine signaling.13-14 Secondly, within the cancer cells, modifications of tumor
suppressor proteins results in their insensitivity towards growth regulation pathways.15-16 These
modifications in the tumor suppressor proteins inactivate the p53 and pRb proteins responsible for
regulation of apoptosis and other natural cell death mechanisms. This gives cancer cells the ability
to evade cell death due to apoptosis and biological aging, which are the third and fourth hallmarks
of cancer.17-18 These first four hallmarks ultimately result in immortality of cancer cells body as
they are able to continuously grow undisturbed from the normal cell processes that would eradicate
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mutated or dysfunctional cells. As these cancer cells continuously grow into a tumor mass, their
demand for nutrients escalates. In this regard, angiogenesis, the development of new blood vessels,
is initiated by the cancer cells as a mechanism to avoid starvation due to continuous growth; this
is the fifth hallmark of cancer.19-20 The sixth distinguishing hallmark of cancer is its ability to
invade other cells through these newly formed blood vessels, resulting in tumor metastasis.21 This
continual growth of tumor cells is further stimulated by its seventh hallmark, its ability to exploit
both aerobic and anaerobic pathways of glucose synthesis as compared to normal cells which are
limited to only aerobic mechanism.22-23 Lastly, while the immune system of the human body
typically recognizes and eliminates disease causing entities, cancer cells have the ability to escape
immune system recognition.12
1.1.1. Cancer Treatment
Currently, no cure has been developed for cancer. However, several treatment techniques
have been developed to control the disease. These treatment techniques include surgery, radiation,
immunotherapy, and chemotherapy. An overview of these techniques is presented in Figure 1.1.
Surgery involves the excision of the tumor from the body. Radiation therapy refers to the use of
x-rays or gamma rays to shrink the tumor. Immunotherapy, a newly developed treatment, uses the
cells involved in the body’s immune response to attack the tumor cells. Chemotherapy is the most
common treatment for cancer and involves the use of medication to treat the cancer. 24-25 Other
treatment techniques such as targeted therapy and hormone therapy have been developed as well,
but they are used less frequently as compared to the other discussed therapeutics.26
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Figure 1.1. Overview of current cancer therapeutics
These current treatments have shown great promise; however, several challenges arise with
these therapeutics. As cancer cells continue to grow, their mutations continue to multiply making
them susceptible to drug resistance.27 In addition, while treatments such as radiation therapy,
chemotherapy and immunotherapy have shown success in killing tumor cells, they also have
harmful effects to normal cells causing many adverse side effects.28-30 For example, radiation
therapy many times can result in nausea, shortness of breath, hair loss and infertility depending on
the location the therapy is applied.30-32 Chemotherapy has similar side-effects to radiotherapy in
addition to urinary/bladder changes and kidney malfunction due to toxicity of the drugs. 28, 33
Immunotherapy, hormone therapy and targeted therapy comprise of biomolecules that activate the
body’s immune system to attack the tumor; thus, they cause less severe side-effects as compared
to radiation and chemotherapy.26, 34 However, the application of these treatment techniques is
limited to only certain types of cancer.29 Thus, design of easily tunable targeted therapeutics
becomes essential to minimize systemic toxicity and drug resistance.
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In this regard, nanomedicine has been widely investigated for targeted therapeutic
applications.35-37 Conventional nanomedicines serve as nanocariers consisting of an outer shell
prepared from materials such as polymers and organic-inorganic nanomaterials and a hollow core
for drug loading.37 As compared to conventional therapeutics, nanomaterials provide several
distinct advantages. Firstly, several studies have shown that these nanocarriers provide protection
of the drug from biodegradation. Secondly, the nanoscale size of the nanocarrier allows enhanced
permeation into cells, ultimately enhancing the therapeutic efficacy of the drug. Furthermore,
these nanocarriers can be functionalized with various targeting ligands to reduce systemic
toxicity.38-41
Current research on chemotherapeutic application of nanomaterials have mainly focused
on carrier free nanodrugs. Drugs such as doxorubicin and paclitaxel have been self-assembled into
nanomaterials through hydrophobic interactions using polymer or inorganic materials as a
matrix.42-43 These carrier free nanodrugs are synthesized via a simple reprecipition reaction where
limited organic solvent is used; thus, eliminating the use of toxic organic solvents for formation of
nanocarriers. Furthermore, as these nanodrugs are engineered through intramolecular interactions
within the drug, high drug loading and release is seen.44-45 Many nanocarriers suffer from low drug
loading due to inadequate interaction between the carrier and the drug, reducing the therapeutic
efficacy of these therapeutics. In addition, those nanocarriers that have strong interactions with the
drug have low drug release at the tumor site again reducing the efficacy. This reduced drug release
can be attributed to the interface between the tumor site and the nanodrug being the nanocarrier
rather than the drug. 40, 46-47 In contrast, in these “carrier free” nanodrugs, the interface between the
nanodrug and the tumor site is the nanoparticle assembly of the drug itself; thus, allowing for
enhanced drug release.48-49 In this regard, many of these new nanodrugs have been employed for
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clinical applications due to their enhanced therapeutic efficacy. Moreover, development of a highly
tunable carrier free nanodrug can provide for an interface for rapid synthesis of an array of highly
effective therapeutics to combat problems such as systemic toxicity and drug resistance. 50
In this regard, our research group has developed highly tunable nanomaterials, i.e.
nanoGUMBOS, derived from a group of uniform materials based on organic salts (GUMBOS).
GUMBOS are comprised of both a cationic and anionic entity and can be synthesized via a simple
ion exchange reaction. The simple and rapid synthesis makes these GUMBOS highly tunable for
various applications.51 Anticancer GUMBOS can be designed through the use of either an
anticancer cation or anion, and this counter-ion variation can lead to numerous unique properties.
Furthermore, GUMBOS can be synthesized using counter-ions that aid in evading biological
processes leading to drug resistance and systemic toxicity in order to combat these problems in
current therapeutics. This dissertation focuses on synthesis, characterization of and
chemotherapeutic examination of rhodamine based nanoGUMBOS.
1.2. ANTICANCER APPLICATIONS OF RHODAMINE DYES
Chemotherapeutic applications of various rhodamine dyes have been examined due to their
ability to penetrate the cell membrane and induce mitochondrial dysfunction. These dyes bind to
the mitochondrial membrane and block oxidative phosphorylation, which serves as the major
pathway of ATP production within the cell.52 The lipophilic characteristic of these rhodamine dyes
allows for enhanced penetration of dye into the cell through interactions with the phospholipid
bilayer. Previous investigation of various hydrophobicity of several cationic structures indicated a
more selective accumulation of rhodamine dyes as compared to triarylmethane dyes such as methyl
and crystal violet. In addition, the cationic charge on some rhodamine derivatives such as
rhodamine 6G (R6G) and rhodamine 123 (R123) provide an electrostatic interaction of the dye
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with the net negative charge of the cell membrane. The combination of both the lipophilic and
cationic characteristics of these rhodamine dyes resulted in partially selective uptake of these dyes
into the mitochondrion of cancer cells.53-54 In-vivo applications of both dyes indicated substantial
toxicity of R6G and R123 at high concentrations to healthy tissue limiting their chemotherapeutic
application.52 While the latter has progressed to clinical trials, the high toxicity of the dye
ultimately prevented its further use. In addition to R6G and RB, rhodamine 110 (R110) and
rhodamine B (RB) have been examined for anticancer applications; however, permeation of the
dye into the cell was hindered due to the zwitterion structure. In addition, for R110 the hydrophilic
nature of the dye resulted in non-selective uptake of the dye such that intracellular localization was
observed in both the cytosol and the mitochondria.55-56 Further investigations indicated
encapsulation of these zwitterion dyes into nanocarriers enhanced therapeutic toxicity since the
interface of the cell membrane is now the nanocarrier rather than the dye. In this dissertation,
chemotherapeutic applications of R6G, R123, R110 and RB based nanoGUMBOS to enhance the
therapeutic potential of these dyes through ion variations.57-58
1.3. GUMBOS
GUMBOS (group of uniform materials based on organic salts) are a new class of ionic
materials developed by the Warner Research Group.51 They are organic salts primarily comprising
of bulky organic or inorganic cationic and anionic moieties that can be tuned via a simple
metathesis reaction. GUMBOS are solid at room temperature with melting point ranges 25-250°C,
in contrast to ionic liquids which have melting points below 100°C. Similar to ionic liquids, ion
variation of GUMBOS can lead to various changes in their chemical and physical properties,
giving them their tunable nature.51 Furthermore, the simple and rapid synthetic route of these
materials give them a distinct advantage over materials requiring lengthy and complex synthesis.
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The cationic or anionic moiety typically determines the application of the compound, making these
materials inherently task-specific for a variety of applications, including cancer therapy, mass
spectrometry, optoelectronic devices, sensors, protein separation, and nanotechnology. These
applications arise from the tunable nature of GUMBOS, which allows for modification of
hydrophobicity, solubility, thermal stability, and photophysical properties through ion variation.
Herein, this dissertation focuses on chemotherapeutic applications of GUMBOS.51
Biomedical applications of GUMBOS have been examined through replacement of the
cation or anionic moiety with a therapeutic ion. The Warner research group has reported
antimicrobial applications of GUMBOS derived from the combination of antibiotic and antiseptic
ions. Intriguingly, the combination of both therapeutic ions into a single GUMBOS led to reduced
toxicity at examined conditions and a synergistic effect between the antibiotic and antiseptic was
observed.59 Similar applications can be examined for chemotherapeutic applications as well. For
example, a targeted therapeutic ion can be combined with a fluorescent probe for fluorescent aided
surgery applications. In this regard, the targeted ion serves to drive the GUMBOS to the tumor
site, and the fluorescence ion will aid in identification of the tumor.38, 60 This allows for more
precise removal of tumor tissue, in addition to treatment of any residual tumor. Furthermore,
targeted therapeutic ions can be combined with other currently toxic therapeutics to create a
targeted compound with dual anticancer properties. Moreover, the tunable nature of GUMBOS
provides an interface for rapid synthesis of innovative combinations of therapeutics that could aid
in reduction of severe side effects and drug resistance.
1.4. NANOGUMBOS
Nanomaterials derived from GUMBOS, i.e. nanoGUMBOS, incorporate the advantages of
GUMBOS into a compact nanoscale material, further broadening the application of these organic
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salts. These nanoGUMBOS have been employed for various applications such as cancer therapy
and biomedical imaging.51,

61-62

In contrast to conventional nanomaterials used in biomedical

applications, these nanoGUMBOS serve as the drug/probe themselves, eliminating the need for
lengthy and complex examination of drug loading/release profiles. In addition, the rapid synthesis
and tunable nature of nanoGUMBOS allows for easy modification to avoid drug resistance.62
1.4.1. Synthesis of NanoGUMBOS
The hydrophobic nature of GUMBOS allows rapid formation of nanoGUMBOS in
aqueous media through various methods. For this dissertation, nanoGUMBOS were prepared
using reprecipitation and ion-association methods depicted in figure 1.2. For the reprecipitation
method, the compound was first dissolved in organic solvent, and a small amount of this solution
was rapidly injected into an aqueous medium, such as water or cell media, under sonication for 5
minutes. After sonication, nanoGUMBOS were left to grow for 30 minutes before further use.62
In the case of ion-association method, both cation and anion were dissolved in an aqueous solvent.
Subsequently, the two solutions were mixed under ultrasonication to develop nanoGUMBOS.
These nanomaterials were then centrifuged, and dried in vacuo to form a nanoparticle pellet.61 In
contrast to reprecipitation, the ion association method provides rapid synthesis of nanomaterials
through integration of GUMBOS and nanoGUMBOS formation in one step.
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Figure 1.2. Schematic of reprecipation and ion association methods for synthesis of
nanoGUMBOS
1.5. SELECTIVE CHEMOTHERAPEUTIC APPLICATIONS OF R6G NANOGUMBOS
Recently in our research group, selective chemotherapeutic applications were examined
for R6G based nanoGUMBOS.62 As indicted in the earlier discussion of anticancer applications of
rhodamine dyes, the R6G dye has been previously examined for anticancer applications by others;
however, its application was limited due to its high toxicity towards normal cells.63 In our research
group, we have found that conversion of the R6G dye into nanoGUMBOS led to selective toxicity
towards cancer cells, with no toxicity to normal cells under examined conditions. Examination of
cellular uptake indicated a profound increase in cellular internalization of dye into cancer cells as
compared to normal cells. Intriguingly, despite minor cellular uptake into normal cells, no toxicity
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to normal cells was observed within the explored experimental parameters. Evaluation of the
hydrophobicity of these compounds indicated selective toxicity of the two most hydrophobic
GUMBOS. These results suggested a dependence of the selective toxicity on the hydrophobicity
of the compound. Additional examinations of more hydrophilic GUMBOS indicated non-selective
toxicity further corroborating this hypothesis.62 This dissertation involves a detailed examination
of the mechanism of selective toxicity of these rhodamine 6G nanoGUMBOS and further examines
other rhodamine derivatives for similar selective chemotherapeutic behavior.
1.6. ANALYTICAL TECHNIQUES
1.6.1. Ultraviolet-Visible Spectroscopy
Ultraviolet visible (UV-Vis) spectroscopy is a powerful analytical technique to quantitate
the attenuation of a beam of light due to molecular absorption of the analyte as light passes through
a sample. UV-Vis spectroscopy can be used for a variety of applications, ranging from simple
examination of photochemistry of a molecule to biomedical applications using colorimetric assays.
The working principle of a conventional UV-Vis spectrophotometer is presented in figure 1.3.
When a beam of light is released from the source, it first passes through a monochromator, where
the light is filtered for a desired wavelength. Subsequently, a beam splitter splits the light into two
paths. One of these beams passes through the sample, and another one that passes through a
reference cell. Finally, a detector then records the amount of light either absorbed or transmitted
by the sample. Typically, molecules that absorb light in the ultraviolet and visible region of the
electromagnetic spectrum will have a characteristic peak that corresponds to the wavelength of
light absorbed. Beer-Lambert’s Law (Beer’s Law) correlates the absorbance to the sample
concentration (c), molar absorptivity (ϵ), and path length of the cuvette (b). This is typically
expressed as A= ϵbc.64
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In this dissertation, absorbance measurements were used to determine cell viability and
cellular uptake following incubation of the synthesized drug. Cell viability measurements were
carried out in either a 96 or 24 well plate; thus, a microplate reader was used in place of a
conventional spectrophotometer. These two instruments operate based on identical principles, with
a slight variation in beam direction. The beam of this microplate reader has a vertical light beam
in contrast to the horizontal light beam of a conventional spectrophotometer. In regards to Beer’s
law, the sample volume replaces the path length in these measurements due to this modification in
beam direction. For the cellular uptake studies, a conventional UV-Vis spectrophotometer is used
to determine the concentration of internalized drug using several calibration standards. A
comparison of the working principle of a multichannel microplate reader to the conventional UVVis spectrophotometer is presented in Figure 1.3.64-65
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Figure 1.3. Working principles of a conventional UV-Vis spectrophotometer and UV-Vis
Microplate Reader
1.6.2. Cytotoxicity Assay
Cytotoxicity assays are typically employed to assess the effect of biological probes or drugs
on the function of various cell processes. Furthermore, examination of cell viability provides
insight into both therapeutic efficacy and biocompatibility of developed compounds. While several
colorimetric assays with varying detection methods have been developed, detection of formazan
dyes is the most common technique.66 Typically, a tetrazolium salt is cleaved into formazan
13

through metabolic reductase enzymes. Since these reductase enzymes are only active in live cells,
the absorbance of the formazan can then be used to ascertain cell viability. The measurements are
dependent upon several factors such as cell type, incubation time, type of assay used and number
of cells.67 Compounds that have an overlap in the absorbance wavelength range with the assay can
cause skewed results, as the absorbance will come from both the formazan and the compound.
Thus, the developed assays come in a variety of detection wavelengths to minimize this
background absorbance. In addition, absorbance of just MTT (3-(4,5 dimethylthiazol-2yl)-2,5diphenyltetrazolium bromide) dye and drug without cells can be used as background absorbance
to remove compound interference as well. In this dissertation, the MTT toxicity assay was used to
access the cytotoxicity of developed GUMBOS. In the presence of live cells, the yellow MTT dye
is cleaved into insoluble purple formazan crystals through the reaction presented in Figure 1.4.
Subsequently, a sodium dodecyl sulfate dimethylformamide solution is used to solubilize the
crystals to create a homogenous purple solution with an absorbance at 570 nm. The absorbance of
this solution is proportional to the number of live cells, as only the cells that are alive will have the
reductase enzyme that causes this purple color.68

Figure 1.4. Enzymatic reaction of the cleavage of MTT to formazan in the presence of
mitochondrial reductase
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1.6.3. Fluorescence Spectroscopy
In addition to absorbance spectroscopy, fluorescence spectroscopy can also be used to
characterize compounds that absorb light in the ultraviolet and visible range of the electromagnetic
spectrum. However, in fluorescence spectroscopy, the amount of light emitted by a molecule as it
decays back to ground state from an excited state is measured, rather than the amount of light
absorbed by a molecule. This phenomenon is typically symbolized using a Jablonski diagram
(Figure 1.5). As the molecule absorbs a photon of light, it is excited from the ground state to an
excited state. Fluorescence is the radiative decay of a molecule from the first excited state, S1,
back to the ground state. Phosphorescence is a radiative decay process that competes with
fluorescence; however, it is less probable. When a molecule in S1 undergoes intersystem crossing
(ISC) to an excited triplet state before it decays to the ground state, that molecule undergoes
phosphorescence. In the case that the fluorophore is excited to an excited state higher than S1, it
must undergo non-radiative decay via internal conversion (IC) to return to S1 prior to fluorescence.
When a photon undergoes IC, it emits less energy than it originally absorbed. Thus, the emission
wavelength of a molecule is always at a longer wavelength as compared to that of excitation. This
shift in the excitation and emission wavelengths is known as Stokes shift.65
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Figure 1.5 Graphical representation of the Jablonski diagram
A typical fluorimeter consists of an excitation and emission monochromator, sample
chamber and detector. Briefly, as the light source releases a beam of light, it is first passed through
an excitation monochromator where it is filtered for a desired wavelength. As the beam of light
passes through the sample, the emitted light is collected perpendicular to the excitation light beam
to prevent interference of the incident light with the sample fluorescence. This emitted light is then
passed through an emission monochromator, which filters stray light for better detection of the
desired wavelength, prior to reaching the detector. As compared to absorbance, all sides of a
fluorescence cuvette must be polished as the emitted light is collected perpendicular to the beam
of incident light, rather than in a straight line. Figure 1.6 shows a graphical representation of this
working principle.65
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Figure 1.6. Working principle of conventional fluorimeter
1.6.4. Fluorescence Microscopy
Biomedical applications of fluorescence typically rely on the integration of the
fluorescence concept described above into a microscope that can aid in visualization of
microstructures within the cell. In contrast to bright field microscopy, that only examines the
sample with white light, fluorescence microscopy can help increase resolution of fine structures
within the cell.69 In this regard, fluorescence microscopy is typically used in conjunction with
staining techniques to examine organelles within the cell. In addition, this technique can also be
employed to examine internalization and cellular localization of fluorescent probes or drugs within
the cell. Furthermore, while fluorescence microscopy is typically used for qualitative detection of
fluorophores within cells, development of new software now allows for quantitation of the
observed fluorescence.70
A fluorescence microscope consists of a light source, excitation filter, emission filter, and
detector. Similar to a fluorescence spectrometer, the excitation and emission filters are used to
filter light for the desired wavelengths. In contrast to a conventional fluorescence spectrometer,
17

due to the upright geometry of the microscope, a dichroic beam splitter is used to reflect the
excitation light onto the sample, and then transmit the emitted light to the detector. A schematic
representation of this instrument is shown in Figure 1.7.69-71

Figure 1.7. Working principle of an upright fluorescence microscope
1.6.5. Transmission Electron Microscopy
Transmission electron microscopy (TEM) is an analytical technique typically used to
characterize the size and morphology of dried-state nanoparticles. The superior resolution of TEM
enables its use in biological applications to image intracellular organelles as a complimentary
technique to light microscopy.72 In this dissertation, TEM microscopy was employed to
characterize the developed nanoGUMBOS. Typical sample preparation involves the deposition of
a small volume (4-8 uL) of nanoparticle solution onto a copper coated grid. Other metals such as
gold, molybdenum and platinum can be used as well depending on the requirements of the sample;
however, copper is the most common. The working principle of TEM is similar to that of a light
18

microscope; however, electrons are used to generate the final image rather than light. 72-73 A
schematic of a TEM microscope is presented in Figure 1.8.
Briefly, electrons are first accelerated out from the electron gun due to a difference in
potential of the cathode (heated tungsten filament) and anode components. The beam of electrons
is then passed through the sample, resulting in scattering and subsequent transmission of the
electrons. Transmission of electrons is primarily dependent upon sample thickness. Typically, 100
nm samples are considered electron transparent, as the thickness allows for the transmitted
electrons to pass through the entire sample. After passing through the sample, these electrons are
focused onto a fluorescent screen or detector, and where intermediate and projector lenses are used
to enlarge the final image.74-75

Figure 1.8. Working principle of a transmission electron microscope
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1.6.6. Dynamic Light Scattering and Zeta Potential
Dynamic light scattering (DLS) and zeta potential are the two most common methods to
characterize nanoparticle size and stability, respectively, in solution state. In contrast to TEM, DLS
uses mathematical algorithms to determine the size of the nanomaterials, rather than produce a
visual representation.76-77 Briefly, as a laser beam irradiates a sample, Brownian motion of the
nanomaterials within the sample causes scattering of the light and subsequent fluctuations of the
intensity of scattered light. The rate of Brownian motion and the rate of fluctuations for the
scattered light is largely dependent upon the size of the particle (i.e., smaller particles cause more
rapid fluctuations in intensity). In this regard, the correlation function generated from the DLS
measurements is based upon the time needed for decay of this signal. The mathematical algorithms
then determine the relative size of the nanoparticle from the signal decay time.78
In addition to size, stability of nanomaterials also plays a major role in their application,
therefore zeta potential measurements are frequently performed to determine nanoparticle
stability.79 The surface charge of the nanoparticle causes a degree of electrostatic repulsion
between adjacent and similarly charged particles, which can ultimately prevent the nanoparticle
from aggregation and precipitation. In this regard, as the surface charge increases, this repulsion
also increases, thus a direct correlation can be made between surface charge and nanoparticle
stability. Typically, zeta potential measurements are representative of the nanoparticle charge at
the interfacial layer between the dispersion medium and the nanoparticle. This interfacial layer,
typically known as the electrical double layer, is generated as the surface charge of the nanoparticle
attracts a thin layer of oppositely charged ions.80 This electrical double layer consists of an inner
stern layer where the oppositely charged ions are strongly adhered on the surface of the
nanoparticle and an outer diffuse region. As a voltage is applied across the sample, a potential is
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generated on the slipping plane of the electrical double layer and the nanoparticle begins to travel
towards the electrode of opposite charge of this potential. This potential is said to be zeta potential
and can be determined from the velocity of the nanoparticles as they migrate through the sample.
Usually, a zeta potential of greater than +30 mV or less than -30 mV indicates a relatively stable
solution.81 In contrast, a zeta potential close to 0 would indicate a high degree of precipitation of
the nanoparticles due to unstable conditions.82
1.7. OVERVIEW OF DISSERTATION
In the presented work, a series of based nanoGUMBOS were synthesized and examined
for their chemotherapeutic properties. Firstly, the previously investigated R6G nanoGUMBOS
were further examined to ascertain the mechanism of selective toxicity. Furthermore, these
nanomaterials were then employed in athymic nude mice to examine in-vivo therapeutic efficacy,
as well as kinetics. Subsequently, in the third chapter, α-HP-CD, β-HP-CD, and γ-CD cyclodextrin
was used to template these nanoGUMBOS in order to reduce their size. The effect of this size
reduction on the toxicity and selective behavior the nanoparticles was then examined in-vitro
studies.
The fourth and fifth chapters of this dissertation examine various rhodamine derivatives
and assess their selective chemotherapeutic properties. In Chapter 4, rhodamine 123 was examined
for its chemotherapeutic applications in breast and pancreatic cancer cells. This dye has previously
been employed for clinical applications; however, its poor toxicity towards cancer cells halted
further testing. Since the R6G nanoGUMBOS displayed selective anticancer applications, similar
examinations for R123 were conducted to give further insight to its potential clinical use. In
Chapter 5, chemotherapeutic applications of GUMBOS based on other rhodamine derivatives such
as rhodamine 110 and rhodamine B were examined. As indicated earlier, due to their zwitterion
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structure, these rhodamine decreased cellular uptake ultimately limiting their use as therapeutics.
Furthermore, while typical rhodamine, such as R123 and R6G, have selective accumulation into
the mitochondria, the acid-base properties of the carboxylic acid group in the zwitterion structure
of rhodamine B and rhodamine 110 causes non-selective accumulation of these compounds.
Previous literature indicated the profound role of hydrophobicity on this selective mitochondrial
uptake. Variation of hydrophobicity through counter-ion exchange could provide more insight to
tuning these compounds for more selective uptake of these dyes into the mitochondria of cancer
cells and enhance their therapeutic potential. GUMBOS are easily tunable organic salts that are
ideal for this application due to their rapid synthetic route. Thus, in Chapter 5, GUMBOS derived
from these zwitterion rhodamines were examined for enhanced chemotherapeutic efficacy as
compared to the respective parent dyes.
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CHAPTER 2
ENDOCYTIC SELECTIVE TOXICITY OF RHODAMINE 6G BASED NANOGUMBOS
2.1. INTRODUCTION
The increasing number of side effects of current chemotherapeutics makes the development
of more targeted therapeutics essential.1 In contrast to conventional chemotherapeutics, nanodrugs
allow for a more targeted therapy; thus, several nanodrugs have been engineered and examined for
chemotherapeutic applications in effort to reduce this systemic toxicity.2-5 Conventional nanodrugs
serve as a nanocarrier composed of either polymeric or organic/inorganic materials with a hollow
inner core for drug loading.6-8 In contrast to conventional theraptueic techniques, these
nanocarriers provide a protective veichle of transport for the drug to the tumor site. Furthermore,
the nanoscale size of these carries allows for enhanced permeation into the cell, ultimately
enhancing the therapeutic efficacy of the drug.3, 6-7, 9 Moreover, these nanocarriers have enhanced
the efficacy of several drugs; however, most of these nanocarriers suffer poor drug loading and
release; thus, the synthetic route requires several lengthy optimizations.10-11, 12
Our group has developed selective chemotherapeutic nanomaterials, nanoGUMBOS,
derived from a group of uniform materials based on organic salts (GUMBOS). GUMBOS are
organic salts with tunable properties, such as hydrophobicity, making them particularly suitable
for several unique applications.13 In contrast to typical nanomaterials that serve only as drug
carriers, nanoGUMBOS can serve as the therapeutic drug, eliminating the need for a matrix. Our
previous study demonstrated that tuning the hydrophobicity of the R6G-based GUMBOS,
followed by production of nanoGUMBOS from such materials, led to selective toxicity towards
the MDA-MB-231 cancer cell line over normal breast cells, despite the nonselective behavior of
the parent dye, [R6G][Cl].14 While previous studies have examined several cations of varying
hydrophobicity for targeting the mitochondrial membrane, to the best of our knowledge our studies
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were the first to investigate tunable hydrophobicity of a single compound for selective cytotoxicity
of nanomaterials.15-17 Subsequently, other research groups have corroborated similar findings and
have begun to investigate tunable hydrophobicity through counter-ion exchanges for several
applications.18-20 In this study, we examine the mechanism of selective toxicity of these
nanomaterials.
Examination of the mechanism of selectivity is essential for development of more efficient
chemotherapeutics. Several studies examining selectivity of nanomaterials have attributed their
selective behavior to targeting agents as well as various internalization pathways; in this work, we
have focused on examination of the latter approach.21 Internalization of nanoparticles in cells
typically occurs through endocytosis.22-30 Endocytosis can occur via two primary pathways:
phagocytosis and pinocytosis. Phagocytosis is generally associated with large particles (2-3 µm),
while pinocytosis is associated with nanoscale particles. Pinocytosis is further divided into three
categories 1) caveolin-mediated endocytosis 2) clathrin-mediated endocytosis, and 3)
micropinocytosis.22-23 In cancer cells, overexpression of certain endocytic proteins is often
observed.24 The nanoparticle size, charge, and shape can be modified for cellular uptake using the
pathways associated with these overexpressed proteins.25 Therefore, a detailed understanding of
the internalization pathway can aid in systematic modification of nano-drugs.26-30
Herein, the role of endocytosis in the selective chemotherapeutic behavior of the R6Gbased nanoGUMBOS was examined using MDA-MB-231 breast cancer and HMEC and Hs578Bst
normal breast cell lines. Since our studies examine internalization of nanomaterials, this
manuscript focuses primarily on pinocytic pathways. In these studies, cell viability as well as
fluorescence microscopy measurements were used in conjunction with various pinocytosis
inhibitors to examine internalization of the R6G-based nanoGUMBOS. In addition, mitochondrial
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and lysosomal staining techniques were employed in order to investigate the cellular localization
of the nanoGUMBOS. Lastly, in vivo studies of the [R6G][BETI] nanoGUMBOS were performed
to evaluate bio distribution and drug efficacy.
2.2. MATERIALS AND METHODS
2.2.1. Materials
Rhodamine 6G (95%), phosphate buffered saline (10x concentrate, 0.2 uM filtered),
methylene chloride, dimethylsulfoxide (DMSO), citric acid monohydrate, sodium phosphate
dibasic, chlorpromazine (98%), filipin III (85%), 5 n-ethyl-n-isopropyl amiloride, 4-(2aminoethyl) benzenesulfonyl ﬂuoride hydrochloride and 0.2 uM nylon filters were purchased from
Sigma-Aldrich (Milwaukee, WI). MitoTracker and LysoTracker dyes were purchased from
Molecular Probes (Eugene, OR). Chloroquine hydrochloride was purchased from InvivoGen (San
Diego, CA). Lithium bis (perfluoroethylsulfonyl) imide was obtained from Dr. Gary Baker (Oak
Ridge National Laboratory, Oak Ridge, TN). Triply deionized water was obtained from an Aires
High Purity Water System (Port Allen, LA). The cell viability MTT (3-[4, 5-Dimethylthiazol-2yl]-2, 5-diphenyltetrazolium bromide) assay was purchased from Promega Corporation (Madison,
WI). TEM grids were purchased from Ted Pella (Redding, CA).
2.2.2. Synthesis of GUMBOS.
The R6G based GUMBOS were synthesized using an anion exchange method outlined in
Magut et.al.1 Rhodamine 6G GUMBOS were prepared using a two-phase ion exchange method
modified from literature.7 Briefly, rhodamine 6G chloride was dissolved in dichloromethane
(DCM) and mixed with an aqueous solution of lithium bis(perfluoroethylsulonyl) imide (BETI) in
a 1:1 mole ratio and 2:1 volume ratio. The biphasic mixture was allowed to stir for 48 h at room
temperature. After stirring for 48 h, deionized water was then used to wash the DCM layer to
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remove lithium chloride by-product. Subsequently, the aqueous layer was removed and the DCM
layer was rotoevaporated. The product was then dried in vacuo to remove trace amounts of water.
2.2.3. Synthesis and characterization of nanoGUMBOS.
R6G based nanoGUMBOS were made through a reprecipitation method outlined in Magut
et.al.1 [R6G][BETI] was dissolved was dissolved in dimethylsulfoxide (DMSO) at 2% of the total
volume). Then, a 1 mM solution of nanoGUMBOS was formed by rapid injection of the DMSO
solution into the cell medium under ultra-sonication for five minutes. The solution was then
allowed to sit for 30 minutes, followed by dilution to 100 µM with cell medium for cell studies.
TEM grids were spotted using 3 µL of nanoGUMBOS solution for characterization.
2.2.4. Study of nanoGUMBOS Dissociation.
R6G based nanoGUMBOS were made using the reprecipitation method described above.
NanoGUMBOS were then diluted in either a phosphate citric acid buffer at pH seven or pH four.
Buffers were made using triply de-ionized water that was filtered with 0.2 uM nylon filters.
2.2.5. Cell culture
In vitro experiments were performed using normal human breast epithelial cells (HMEC),
normal human breast fibroblast breast cells (Hs578Bst) and hormone-independent human breast
adenocarcinoma cells (MDA-MB-231) obtained from the American Tissue Culture Collection
(ATCC, Manassas, VA). These cells were cultured according to the recommendations of the
supplier. HMEC cells were cultured in Lonza Mammary Epithelial Growth Medium with Lonza
MGEM Bullet Kit. MDA-MB-231 cells were cultured in Leibovitz's L-15 Medium containing
10% fetal bovine serum FBS.
2.2.6. Cell viability measurements.
Cell viability measurements were performed using 24 well plates using an MTT Assay kit
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(Promega Corporation, Madison WI, USA). In each well of the 24-plate, 100,000 MDA-MB-231
cells were seeded in 0.5 mL of cell media and incubated at 37°C and 5% CO2 for 24 h. Following
the 24 h incubation, the media was then replaced with 0.5 mL of cell media containing 7 µg/mL,
3 µg/mL or 2.9 µg/mL of chlorpromazine, filipin III, and amiloride respectively. For the control
wells with no inhibitor, the media was replaced with 0.5 mL of fresh cell media without inhibitor.
After 2 h., the media containing the inhibitor was then replaced with 0.5 mL of nanoGUMBOS in
cell media. After addition of the nanoGUMBOS, the cells were incubated for 48 h at 37°C and 5%
CO2. Following a 48 h incubation, an MTT assay was performed to observe cytotoxicity based on
the Promega protocol. In brief, the MTT dye (150 µL) was added to each well and incubated for 4
h at 37°C and 5% CO2. The MTT dye reacts with the NAPDH enzyme in live cells to form an
insoluble purple formazan compound. Then, 1000 µL of the stop solution, consisting of 10% HCL
in SDS buffer, were added to each well and incubated for another hour to dissolve the formazan
and terminate the enzymatic reaction of the MTT dye with the NADPH enzyme. Absorbance
measurements were obtained using a multichannel microplate spectrophotometer (Benchmark
Plus; Bio-Rad Laboratories, Hercules, CA) at 570 nm. For cell viability calculations, the
absorbance ratio was calculated between the cells treated with nanoGUMBOS and untreated cells,
assuming 100% cell viability for the untreated control. A similar protocol was used for the
lysosomal inhibitors with modification of concentration based on literature.
2.2.7. Fluorescence microscopy.
MDA-MB-231 breast cancer, Hs578Bst and HMEC cell lines were used for microscopy
studies. In brief, approximately 10,000 cells were seeded in three mL of cell media on a 25 mm
glass bottom petri dish (10 mm micro cell; Ashland, MA, USA) and incubated at 37°C for 24 h.
After 24 h, cells were then pre-incubated with cell media containing 7 µg/mL, 3 µg/mL or 2.9 µM
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of chlorpromazine, Filipin III, and amiloride inhibitor respectively for 2 h. For the sucrose and K+
depletion inhibitor studies, cells were incubated with sucrose supplemented PBS, K+ Free HEPES
buffer, or the respective controls PBS buffer and K+ Supplemented HEPES buffer for 1 h. After
incubation, the inhibitor solution was removed from the cells and replaced with 25 uM of either
[R6G][BETI] or [R6G][Cl], and cells incubated for another 30 minutes. Following compound
incubation, the cells were washed with PBS. Fluorescence images were taken using a 40× dipping
objective lens with the TRITC (excitation 535 ± 15 and emission 575 ± 15) fluorescence filter on
the Leica DM RXA2 fluorescence microscope for the endocytosis studies.
For studies with MitoTracker and LysoTracker, 1 mM DMSO stock solutions of
LysoTracker and MitoTracker were diluted to 15 and 10 nM in cell media respectively.
NanoGUMBOS were diluted to a 25 nM working concentration in cell media. Cells were first
incubated with 15 nM LysoTracker solution for 20 minutes. This solution was then removed and
cells were washed with cell media to remove any excess dye. A 10 nM MitoTracker solution was
then incubated with the cells for 20 minutes. Following incubation, cells were washed again with
cell media to remove any excess dye. Finally, cells were incubated with the 25 nM nanoGUMBOS
solution for 30 minutes. This solution was then removed and cells were washed with PBS buffer
to remove excess dye. Cell media was replaced with PBS buffer for imaging.
2.2.8. In vivo studies.
Athymic nude mice were used for in vivo studies employing an IACUC approved protocol.
Mice were injected with MDA-MB-231 cancer cells and the tumor formed was treated using R6G
nanoGUMBOS. The tumor was allowed to grow for 41 days followed by subsequent injection of
PBS buffer, 0.16 mg/kg [R6G][BETI] nanoGUMBOS or 1.6 mg/kg [R6G][BETI] nanoGUMBOS.
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2.2.9. Statistical analysis.
A t-test was performed to ensure significant differences in cell viability with and without
inhibitor and in-vivo examination. Significance was determined using p=0.05 (95% confidence
level) for the inhibitor studies. In the case of in-vivo studies, significance was determined using a
two-way ANOVA analysis. All results were measured in triplicate and expressed as mean cell
viability % ± SD.
2.3. RESULTS AND DISCUSSIONS
2.3.1. Synthesis and Characterization of GUMBOS and nanoGUMBOS
R6G based GUMBOS were synthesized using an ion-exchange reaction reported in Magut,
et.al (Figure 2.1)15 Subsequently, nanoGUMBOS were synthesized using a reprecipitation method
as outlined in the methods section of that manuscript. Endocytic uptake of nanomaterials can occur
via caveolin -mediated endocytosis, clathrin-mediated endocytosis, or micropinocytosis depending
upon nanoparticle size, shape and charge. Thus, characterization of nanoGUMBOS is essential to
understanding the mechanism of cellular uptake. In this study, transmission electron microscopy
(TEM) was used to characterize the size and shape of [R6G][BETI] nanoGUMBOS. The TEM
image and histogram of the size distribution (Figure 2.2) indicate spherical nanoGUMBOS with a
size of approximately 100 nm diameter. Previous literature has demonstrated that spherical
nanomaterials with sizes around 100 nm are optimal for a clathrin-mediated pathway.22 Therefore,
we anticipate that uptake of our [R6G][BETI] nanoGUMBOS should occur via clathrin-mediated
endocytosis.
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Figure 2.1. Scheme of [R6G][BETI] Synthesis

Figure 2.2. TEM Image and size distribution of [R6G][BETI] nanoGUMBOS
2.3.2. Endocytosis Studies
Following TEM characterization, the internalization mechanism of the nanoGUMBOS was
examined using cell viability assays and fluorescence microscopy. Firstly, MDA-MB-231 cancer
cells were incubated with both the nanoGUMBOS and [R6G][Cl] at low temperature (4°C) in
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order to disrupt energy dependent internalization pathways.31 Subsequently, fluorescence
microscopy images were examined to ascertain cellular uptake of the compound. As shown in Fig.
2.3, incubation of R6G nanoGUMBOS at low temperatures resulted in diminished fluorescence
intensity as compared to the control at 37 °C, demonstrating the use of an energy dependent
pathway of internalization such as endocytosis. In contrast, the [R6G][Cl] fluorescence intensity
was unaffected at low temperatures indicating that this compound employs an energy independent
pathway of internalization such as diffusion.

Figure 2.3. [R6G][BETI] (25 nM) and [R6G][Cl] (25 nM) incubated at 37°C and 4 °C in MDAMB-231 cancer cells
As endocytosis is a major energy dependent pathway for internalization of nanoparticles,
the role of endocytosis in the internalization for nanoGUMBOS was studied using several
endocytosis inhibitors in conjunction with fluorescence microscopy. Three inhibitors [Filipin III,
chlorpromazine hydrochloride, and 5 N-ethyl-N-isopropyl amiloride (amiloride)] were used to
block caveolin-mediated endocytosis, clathrin-mediated endocytosis, and micropinocytosis
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respectively.32-34 As seen in Figure 2.4, cancer cells incubated with [R6G][BETI] nanoGUMBOS
displayed a significant reduction in fluorescence intensity in the presence of chlorpromazine and
as compared to a control with only drug. While diminished fluorescence intensity was also
observed in the presence of Filipin III, an inhibitor for caveolin mediated endocytosis, this can be
attributed to lack of specificity of the inhibitor. Dutta, et.al reported that Filipin III can also block
clathrin mediated endocytosis in addition to caveolin mediated pathways.35 This suggests that
while the role of caveolin mediated endocytosis is unclear, uptake of these nanoGUMBOS in
cancer cells occurs primarily through a clathrin-mediated pathway. Similar results were observed
for the [R6G][TPB] nanoGUMBOS as well. In contrast, fluorescence intensity of [R6G][Cl],
[R6G][OTF] and [R6G][Asc] was unaffected by endocytosis inhibitors indicating internalization
independent of endocytosis in cancer cells.
This variation in internalization behavior between the different compounds is most likely
due to a significant difference in hydrophobicity between these anion variations. Hydrophobicity
of all GUMBOS were confirmed using octanol water partition coefficients and the results were
consistent with that of Magut et al. In this regard, Magut et al. found that while [R6G][BETI] and
[R6G][TPB] are more hydrophobic than the parent dye [R6G][Cl], [R6G][OTF] and [R6G][Asc]
were more hydrophilic. Thus, while [R6G][BETI] and [R6G][TPB] GUMBOS formed
nanomaterials in aqueous medium, the latter two GUMBOS were unable to form nanomaterials
due to their hydrophilic nature. Additionally, Magut et al. reported that only [R6G][BETI] and
[R6G][TPB] were found to display selective toxicity towards cancer cells. 15 Since only
[R6G][BETI] and [R6G][TPB] employed endocytic internalization into cancer cells, this suggests
that endocytic internalization might play a major role in the selective behavior.
Thus, in order to further elucidate the role of endocytosis on the selective nature of the
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nanoGUMBOS, endocytic internalization of the most hydrophobic GUMBOS, [R6G][BETI], and
the parent dye, [R6G][Cl], was further investigated in Hs578Bst normal breast cells (Figure 2.5).
Interestingly, neither compound displayed a reduction in fluorescence intensity in the presence of
endocytosis inhibitors. These results indicate endocytosis dependent internalization of the
[R6G][BETI] nanoGUMBOS in cancer cells, and internalization independent of endocytosis in
normal cells. In contrast, [R6G][Cl] most likely uses a passive mode of internalization for both
cancer and normal cells. Subsequently, to further confirm these results, internalization
[R6G][BETI] nanoGUMBOS and [R6G][Cl] was also examined in HMEC normal epithelial breast
cells (Figure 2.6). Since most breast cancer arises from mutation of epithelial cells, these results
will give further insight to future therapeutic use of these nanoGUMBOS.36 Similar to the results
of Hs578Bst normal cells, no change in fluorescence intensity for either compound was observed
in the presence of the inhibitors suggesting internalization independent of endocytosis. Thus, these
results indicate that clathrin-mediated endocytosis is the major internalization mechanism for the
[R6G][BETI] nanoGUMBOS in cancer cells, while their internalization in normal cells is
independent of endocytosis.
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Figure 2.4. (A) [R6G][BETI], (B) [R6G][TPB], (C) [R6G][OTf], (D) [R6G][Asc], and (E)
[R6G][Cl], with 3 µg/mL, 7 µg/mL, and 2.9 µg/mL of filipin III, chlorprozamine, and amiloride
respectively in MDA-MB-231 cancer cells
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Figure 2.5. (A) R6G][BETI] and (B) [R6G][Cl]with 3 µg/mL, 7 µg/mL, and 2.9 µg/mL of filipin
III, chlorprozamine, and amiloride respectively in Hs578Bst breast normal cells

Figure 2.6. [R6G][BETI] and [R6G][Cl] with 3 µg/mL, 7 µg/mL and 2.9 µg/mL of filipin III,
chlorpromazine and amiloride respectively in HMEC normal breast cells
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In order to further confirm our observations from the endocytosis inhibitors, fluorescence
microscopy of the [R6G][BETI] and [R6G][Cl] was also performed in the presence of hypertonic
and potassium (K+) depletion solutions. Previous studies have shown that hypertonic solutions and
depletion of potassium can disrupt formation of clathrin coated pits.31,
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Here, sucrose

supplemented PBS buffer and a K+ free HEPES buffer serves as the hypertonic solution and K+
depletion solution respectively. As depicted in Figure 2.7, a significant reduction in fluorescence
intensity was observed for [R6G][BETI] nanoGUMBOS in the presence of both the hypertonic
and K+ depletion conditions as compared to their respective controls in cancer cells. These results
suggest that nanoGUMBOS primarily use clathrin mediated endocytosis for internalization into
cancer cells, and disruption of the clathrin coated pit formation inhibited internalization. In
contrast, no change in the fluorescence intensity was observed for [R6G][Cl] as compared to the
control, supporting the conclusion that [R6G][Cl] internalizes via an endocytosis independent
pathway. Furthermore, no change in the fluorescence intensity was observed in the breast normal
cells for either compound (Figure 2.8). These results corroborate the previous microscopy results
that while [R6G][BETI] nanoGUMBOS internalize via an endocytic pathway in breast cancer
cells, internalization of [R6G][BETI] into breast normal cells is independent of endocytosis.
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Figure 2.7. [R6G][BETI] and [R6G][Cl] incubated in MDA-MB-231 breast cancer cells in the
presence of HEPES buffer with and without KCl and PBS Buffer with and without sucrose.

Figure 2.8. [R6G][BETI] and [R6G][Cl] incubated in HMEC normal breast cells in the presence
of HEPES buffer with and without potassium chloride(KCl) and PBS Buffer with and without
sucrose
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As a final confirmation of the use of clathrin-mediated endocytosis in the internalization
for the nanoGUMBOS in cancer cells, cell viability measurements were examined in conjunction
with filipin III, chlorpromazine, and amiloride. Previous investigations have demonstrated toxicity
of these rhodamine-based compounds towards MDA-MB-231 breast cancer cells.15 For these
studies, the cytotoxicity of [R6G][BETI] nanoGUMBOS and aqueous [R6G][Cl] were tested after
blocking each endocytic pathway. An increase in cell viability in the presence of certain inhibitors
could signify the use of that pathway for cellular uptake. Cell viability studies of [R6G][Cl] and
[R6G][BETI] with and without inhibitors are shown in Figure 2.9. Samples containing only
inhibitor and no drug were used as a control to ensure a nontoxic concentration of inhibitor.
Furthermore, all samples incubated with the inhibitor were compared against a control containing
only drug without inhibitor. In the presence of the chlorpromazine inhibitor, a significant increase
in cell viability in cancer cells was observed with [R6G][BETI] nanoGUMBOS in contrast to the
control without inhibitor. When examining the cytotoxic effect of the original dye (i.e.,
[R6G][Cl]), an increase was seen in cell viability in the presence of chlorpromazine as well.
However, this increase is relatively small as compared to our nanoGUMBOS. No increase in cell
viability was observed with filipin III or amiloride inhibitors, suggesting that nanoGUMBOS are
not internalized using these pathways. Examination of these studies in HMEC normal cells,
presented in Figure 2.10, shows no change in cell viability in the presence of the inhibitors,
suggesting internalization independent of endocytosis in normal cells. Thus, these results are
consistent with out previous results that nanoGUMBOS employ clathrin-mediated endocytosis for
uptake in cancer cells while their internalization in normal cells is independent of endocytosis.
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Figure 2.9. Cell viability of R6G compounds in the presence of 3 µg/mL, 7 µg/mL and 2.9 µg/mL
of filipin III, chlorpromazine and amiloride respectively. The cell viability results were compared
using a Student’s t-test; the differences were considered statistically significant if p ≤ 0.05 (*)

Figure 2.10. Cell viability of R6G compounds in the presence of 3 ug/mL, 7 ug/mL and 2.9 ug/mL
of filipin III, chlorpromazine and amiloride respectively in HMEC normal cells
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2.3.3. Examination of mitochondrial uptake using fluorescence microscopy
Results from endocytosis studies indicate that uptake of our nanoGUMBOS in cancer cells
occurs primarily via a clathrin-mediated pathway. This implies that the nanoGUMBOS first pass
through the lysosome and eventually accumulate in the mitochondria. Thus, to further investigate
these results, fluorescence microscopy was used to examine the cellular localization of
[R6G][BETI] nanoGUMBOS and [R6G][Cl] in MDA-MB-231 cancer cells as well as HMEC
normal cells. A micrograph of the rhodamine compounds incubated with MitoTracker and
LysoTracker in cancer cells and normal cells is shown in Figure 2.11. Colocalization of the
MitoTracker with [R6G][BETI] and [R6G][Cl] in both cancer and normal cells, indicates
accumulation of R6G-based compounds in the mitochondria. The merged image of the
LysoTracker and the R6G-based compounds in cancer cells shows colocalization of the
LysoTracker and [R6G][BETI] nanoGUMBOS, implying interaction of the nanoGUMBOS with
the lysosome. However, colocalization in normal cells between the LysoTracker and the
compounds is reduced as compared to that of cancer cells, suggesting that the nanoGUMBOS
experience a less acidic environment in normal cells. These results further confirm the conclusions
gleaned from endocytosis data.
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Figure 2.11. [R6G][BETI] (50 nM) and [R6G][Cl] (50 nM) with mitotracker green (10 nM) shown
as green fluorescence, and lysostracker deep red (20 nM) shown as light blue fluorescence in
MDA-MB-231 breast cancer cells and HMEC normal Cells
2.3.4. Lysosomal Inhibitors
As a final confirmation of the endocytosis mechanism, toxicity of the nanoGUMBOS in
the presence of lysosomal inhibitors was examined. Clathrin-mediated endocytosis requires the
nanoparticle to pass through the acidic lysosome before release into the mitochondria.38 Thus, cell
viability studies were examined in the presence of lysosomotrophic inhibitors to examine the role
of lysosomal acidification or lysosome enzymes, such as proteases, on the nanoGUMBOS toxicity.
The cell viability studies show that the toxicity of [R6G][BETI] is significantly reduced in the
presence of the inhibitor chloroquine (Figure 2.12). However, the toxicity of [R6G][Cl] was
unaffected by the lysosomotropic inhibitor. TEM images presented in Figure 2.13 indicate loss of
nanoparticle shape, suggesting dissociation at acidic pH of the nanoGUMBOS within the
lysosome. In addition, DLS results, Figure 2.14, indicate a loss of signal at acidic pH further
confirming the results from TEM. Further, cytosine and serine protease enzyme inhibitors were
tested to examine the effect of the associated enzymes on the toxicity of our nanoGUMBOS
(Figure 2.15). The toxicity of the nanoGUMBOS was unaffected in the presence of these
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inhibitors. Thus, these results suggest that our nanoGUMBOS dissociate in cancer cells through
lysosomal acidification following endocytic uptake. However, in the case of normal cells, no
dissociation would occur due to uptake using a different mechanism.

Figure 2.12. Cell viability of R6G compounds in the presence of 100 µM of chloroquine to prevent
lysosomal acidification. The cell viability results were compared using a Student’s t-test; the
differences were considered statistically significant if p = 0.05 (*)

Figure 2.13. TEM Images of [R6G][BETI] in different pH buffers
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Figure 2.14. Dynamic Light Scattering (DLS) plot of particle size distribution function vs. decay
time at physiological and lysosomal pH

Figure 2.15. Cell viability of R6G compounds in the presence of 0.5 mM 4-(2aminoethyl)benzenesulfonyl fluoride hydrochloride (AEBSF Inhibitor) and 100 µM E64 inhibitor
that was used to block serine and cytosine proteases respectively
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2.3.5. Mechanism of Selective Toxicity
Results from examination of the endocytosis studies indicate uptake of [R6G][BETI]
nanoGUMBOS primarily via clathrin-mediated endocytosis in cancer cells and uptake
independent of endocytosis in normal cells. While a decrease in fluorescence intensity of
[R6G][BETI] in MDA-MB-231 cancer cells was observed in the presence of Filipin III, an
inhibitor for caveloin-mediated endocytosis, this is attributed to the ability of the inhibitors to block
some clathrin pathways as well. Thus, while the role of caveolin-mediated pathways on the
internalization of nanoGUMBOS is still uncertain, one can conclude from these studies that
clathrin-mediated endocytosis plays a major role in nanoGUMBOS uptake. Use of clathrin
mediated endocytosis was further corroborated using lysosomal inhibitors. Our examination of
lysosomal inhibitors in conjunction with cell viability analysis indicates an increase in cell viability
in the presence of chloroquine, an endosomal acidification inhibitor. Thus, we were able to
conclude that lysosomal acidification following endocytic uptake plays a crucial role in the
selective toxicity of the nanoGUMBOS. The TEM images and DLS results (Figures 2.13 and 2.14)
indicated dissociation of our nanoGUMBOS at lysosomal pH. Therefore, when clathrin-mediated
endocytosis is employed for nanoGUMBOS penetration into cancer cells, the acidic pH (4.3) of
the lysosome likely results in dissociation of the nanoGUMBOS, activating their toxicity to cancer
cells.38 Furthermore, uptake of the nanoGUMBOS in normal cells is independent of endocytosis;
thus, no dissociation of the nanoparticle occurs, leading to their nontoxic nature towards normal
cells. In the case of [R6G][Cl], no dissociation is needed to activate the toxicity due to its high
solubility in aqueous systems, resulting in its inherent toxicity towards both cancer and normal
cells. This overall mechanism is portrayed in figure 2.16.
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Figure 2.16. Endocytic mechanism of selective toxicity of the R6G nanoGUMBOS
2.3.6. In vivo examination
Following our examination of the in vitro mechanism of selectivity, in vivo kinetic and
toxicity studies of [R6G][BETI] nanoGUMBOS were evaluated to further understand their
potential application as chemotherapeutics. Kinetic studies were performed using both an
intraperitoneal (IP) and intravenous (IV) injection to assess nanoGUMBOS accumulation within
the body cavity of the mouse over time. Mice injected IP displayed a significant decrease in
fluorescence intensity over time suggesting gradual excretion of the GUMBOS (Figure 2.17).
However, mice injected IV displayed no change in fluorescence intensity indicating that the
nanoGUMBOS are unable to easily circulate throughout the body. This is most likely due to the
relatively high hydrophobicity of the nanoGUMBOS, ultimately leading to agglomeration within
the blood. Furthermore, the size of the nanoparticles investigated are around 100 nm; however,
literature suggests that 60-80 nm is the optimal size for biomedical applications.3 In this regard,
Chapter 3 of this dissertation employs cyclodextrin templating to aid in formation of reduced size
nanoparticles.

51

Following kinetic studies, we also pursued in vivo toxicity studies of these [R6G][BETI]
nanoGUMBOS to determine if therapeutic properties would be maintained in vivo. For our
examination of tumor reduction, MDA-MB-231 cancer cells were used to produce a tumor on the
right hind leg of 12 athymic nude mice. The volumes of the tumors in these mice were monitored
before and after treatment with [R6G][BETI] nanoGUMBOS as shown in Figure 2.18. In these
studies 0.16 mg/kg [R6G][BETI] nanoGUMBOS, and 1.6 mg/kg of [R6G]BETI] nanoGUMBOS
were injected into two groups of mice respectively, with four mice per group, at the tumor site on
days 41, 47 and 51. A third group of 4 mice treated only with saline solution was used as a control.
Control mice showed a continuous increase in tumor volume. However, mice injected with
[R6G][BETI] showed a 50% reduction in the tumor volume. These studies suggest that
[R6G][BETI] nanoGUMBOS not only inhibit tumor growth but also reduce tumor volume in mice
by almost 50%. In addition, similarities in therapeutic efficacy of the nanoGUMBOS with the two
different doses can be attributed to saturation of the drug within the tumor at the lower dose.
Furthermore, the lack of further decrease in tumor volume can most likely be attributed to the
formation of necrotic tissue at the surface of the tumor; thus, preventing penetration of the
nanoGUMBOS deeper in the tumor tissue. 39
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Figure 2.17 In vivo bio-distribution studies using IP and IV injections
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Figure 2.18 In-vivo tumor reduction using 0.16 and 1.6 mg/kg of [R6G][BETI] as compared to a
saline control. Tumor measurements were compared by a two-way ANOVA and a Bonferroni
post-test; the differences were considered statistically significant if p = 0.05 (*). The arrows
represent days of injection for the mice
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2.4. CONCLUSIONS
The studies reported here demonstrate the profound role of endocytosis in both the
internalization and selectivity mechanisms of R6G nanoGUMBOS as in vitro therapeutic agents
for cancer cells, and also confirm retained therapeutic properties in vivo. It was observed that use
of a clathrin-mediated pathway by the nanoGUMBOS in cancer cells led to nanoparticle
dissociation in the acidic environment of the lysosome, ultimately activating their toxicity.
However, since the nanoGUMBOS did not employ endocytic internalization in normal cells, no
dissociation of the nanoparticle occurs, resulting in their nontoxic behavior towards normal cells.
After thoroughly examining this selectivity mechanism, nanoGUMBOS were employed in vivo to
assess biodistribution and therapeutic efficacy. Remarkably, following nanoGUMBOS treatment,
a 50% reduction in tumor volume was observed in athymic nude mice. Thus, we conclude that
therapeutic properties of nanoGUMBOS are retained during in vivo applications. Moreover, these
in vitro and in vivo studies have enhanced our understanding of R6G nanoGUMBOS and give
further insight to the potential of these novel compounds for chemotherapeutic applications.
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CHAPTER 3
ENHANCED CHEMOTHERAPEUTIC APPLICATIONS OF CYCLODEXTRINTEMPLATED R6G-BASED NANOGUMBOS
3.1. INTRODUCTION
Despite several advancements in treatment, cancer remains the second leading cause of
death as of 2016.1 Current chemotherapeutics suffer from numerous side effects making
development of more selective therapeutics essential.2-3 In this regard, nanomedicines have
demonstrated a more targeted therapeutic delivery in comparison to conventional
chemotherapeutics. Conventional nanomedicines serve as nanocarriers that encapsulate the drug
to aid in therapeutic delivery.4-6 Such nanocarriers are able to protect the drug bio-degradation and
rapidly permeate the cell membrane due to nanoscale size, providing several advantages to
chemotherapeutic drug delivery.7-9 More current research on nanomedicine focuses on the
development of nanodrugs fabricated from hydrophobic drugs, such as paclitaxel, in conjunction
with a polymeric or inorganic matrix.10-11 This removes the need for a carrier as the nanoparticle
is primarily composed of the drug itself, while the polymeric or inorganic template simply aids in
formation of the nanoparticle structure. These carrier free nanodrugs have shown promising
toxicity in vitro and in vivo and are currently being employed for clinical trials as well.
Therapeutic investigations of various nanoparticles indicate a strong correlation between
size, material, hydrophobicity, and surface charge of the nanodrug to its toxicity. Size, in
particular, was found to play a major role in rapid uptake of nanomaterials into the tumor cells.12
In vivo investigations have demonstrated enhanced permeation of the nanomaterials into tumor
tissue due to the leaky tumor vasculature. In this regard, the nanoscale size of the nanoparticle
allows for increased permeation into cancer cells through a phenomenon known as the enhanced
permeability and retention (EPR) effect.13-15 Additionally, in vitro investigations have shown that
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nanoparticles typically internalize using various size-dependent active transport pathways. In this
regard, these studies have demonstrated that tuning the size of nanoparticles to around 60-80 nm
led to enhanced cellular uptake and, ultimately, enhanced toxicity.16-19 Thus, it becomes essential
to develop an approach to rapidly tune size and uniformity of the nanomaterial to optimize the
toxicity. However, the challenge associated with controlled size of current nanodrugs that employ
polymeric and inorganic materials is the complex and labor intensive synthetic route.20 Therefore,
development of a simple method to control the size and uniformity of the nanoparticles becomes
essential.
Our research group has developed nanoGUMBOS, i.e nanomaterials derived from a group
of uniform materials based on organic salts (GUMBOS), which have several unique applications.21
GUMBOS are organic salts synthesized using a simple ion-exchange reaction. The variation in
counter-ions results in several tunable properties, such as hydrophobicity, conductivity, and
melting point, giving these materials a wide variety of applications, including selective
chemotherapeutic toxicity.22 NanoGUMBOS have several distinct advantages over conventional
nanomedicines such as simple synthesis, as well as the ability to serve as the drug rather than the
drug carrier. In these studies, we investigate the effect of cyclodextrin (CD) templating on the size
and in vitro cytotoxicity of nanoGUMBOS derived from rhodamine 6G (R6G), a fluorescent
lipophilic cation known to have promising anticancer properties.23
CDs are oligosaccharides that are typically used for drug encapsulation in order to enhance
the solubility of hydrophobic drugs.24-26 They are usually classified into three classes (α-CD, βCD, and γ-CD) that vary in cavity sizes, with γ-CD being the largest and α-CD being the smallest.
This varying cavity size allows for optimization of the interaction between the drug and the CD.
For example, drugs molecules with large benzene rings are more likely to be encapsulated using β
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or γ-CD rather than α-CD.27 Recent studies found that the hollow, and hydrophobic cavity of
cyclodextrin can also serve as a template to control size and uniformity of the nanoparticles. 28-31
Specifically, studies by Hamden et al. revealed that use of cyclodextrin to template nanoGUMBOS
produced smaller and more uniform nanomaterials.28 In contrast to conventional polymer and
inorganic templates currently being employed for nanodrug fabrication, the relatively higher water
solubility of CD improves therapeutic delivery.32 Furthermore, the simple synthesis of the CD
templated nanoGUMBOS using the ion-exchange technique provides a distinct advantage over
other silica and polymeric based nanomaterials that rely on complex synthesis for reduction in
nanoparticle size. Herein, we report the effect of templating with hydroxypropyl-alpha (HP-α-CD),
hydroxypropyl-beta (HP-β-CD), and gamma (γ-CD) on the size and therapeutic properties of R6G
based nanoGUMBOS.
3.2. MATERIALS AND METHODS
3.2.1. Materials
Rhodamine 6G (95%), phosphate buffered saline (10x concentrate, 0.2 uM filtered),
sodium tetraphenylborate [Na][TPB], methylene chloride, dimethylsulfoxide, citric acid
monohydrate, HP-α-CD, HP- β-CD, and 0.2 uM nylon filters were purchased from Sigma-Aldrich
(Milwaukee, WI). γ-CD was purchased from Fluka (Germany). Sodium phosphate dibasic was
purchased from Fisher Scientific (Fair Lawn, New Jersey). Lithium bis (perfluoroethylsulfonyl)
imide ([Li][BETI]) was obtained from Ionic Liquid Technologies (Tuscaloosa, Al). Triply
deionized water was obtained from an Aires High Purity Water System (Port Allen, LA). The MTT
(3-[4, 5-Dimethylthiazol-2-yl]-2, 5-diphenyltetrazolium bromide) cell viability assay was
purchased from Promega Corporation (Madison, WI). TEM grids were purchased from Ted Pella
(Redding, CA).
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3.2.2. Synthesis of nanoGUMBOS
A 2 mM solution of [R6G][Cl] with and without cyclodextrin (0.8 mg) was mixed with a
2 mM solution of [Li][BETI] or [Na][TPB]. An ultrasonic processor was used to probe sonicate
this solution at 20% amplitude at 30 mhz. The solution was then centrifuged twice at 35,000 rpm
for 30 minutes using a Beckman L8-70M Ultracentrifuge while washing the pellet in between runs
to remove excess cyclodextrin, and [Li][Cl] byproduct. Finally, the product was dried by removal
of water in vacuo. All nanoGUMBOS were resuspsended under ultrasonication for 2 h in cell
media to ensure homogeneity prior to cell studies.
3.2.3. Dynamic Light Scattering and Zeta Potential
NanoGUMBOS were resuspended in 0.01 M PBS buffer to make a 100 µM solution. These
nanoGUMBOS were then diluted to 5 µM for dynamic light scattering (DLS) and zeta potential
measurements.
3.2.4. Cell Culture
MDA-MB-231 breast adenocarcinoma cells, Mia-Paca pancreatic carcinoma and
Hs578Bst normal breast fibroblast cells were purchased from the American Tissue Culture
Collection (ATCC, Manassas, VA). All cell lines were grown to 90% confluency according to the
ATCC guidelines prior to plating.
3.2.5. Cytotoxicity Studies
A 96 well plate was seeded with 5000 cells/well and incubated for 24 h to allow the cells
to attach. Cells were treated with a serial dilution of the nanoGUMBOS from 100 µM to 1.56 µM
of nanoGUMBOS and the last row was kept as an untreated control with only cell media. An MTT
assay was then performed to determine cell viability. In brief, the cells were treated with 15 µL of
MTT assay and incubated for 3 hrs. Then, 100 µL of stop solution was added to solubilize the
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purple formazan crystals. A microplate spectrophotometer was used to measure the absorbance at
570 nm. Cell viability was calculated as a percentage of the ratio between absorbance of treated
cells and absorbance of an untreated control containing only cell media. All measurements were
carried out in triplicate, and reported cell viabilities represent an average of these measurements.
3.2.6. Cellular Uptake Studies
The cellular uptake studies were performed in triplicate using 35 mM petri dishes plated
with 200,000 cells/dish for 24 hrs. The cells were treated with a 5 µM nanoGUMBOS solution and
incubated at 37°C for 5 hrs. The control sample was only incubated with fresh cell media without
nanoGUMBOS. Following the 5 h incubation, it was assumed that some of the nanoparticles had
internalized. Thus, the cell media was removed and the cells were washed with PBS buffer several
times to remove excess compound that was not internalized. The cells were then treated with 3 mL
of DMSO for 5 h to lyse the cells open and release any internalized drug. Subsequently, absorbance
measurements of the DMSO solution were examined using the control cells treated with only cell
media was used as the reference. A set of five DMSO calibration standards from 1-10 µM, were
prepared in triplicate for each nanoGUMBOS, and the absorbance of each solution was recorded.
The internalized concentration of nanoGUMBOS present in the DMSO of the treated cells was
calculated using the linear equation generated from calibration curve of the standards.
3.3. RESULTS AND DICUSSIONS
3.3.1. Characterization of nanoGUMBOS
R6G nanoGUMBOS were synthesized via an ion-exchange reaction between [R6G][Cl]
and lithium bis (perfluoroethylsulfonyl)imide [Li][BETI] or sodium tetraphenylborate [Na][TPB]
to from [R6G][BETI] and [R6G][TPB] respectively. The ion-exchange reaction was performed
under ultrasonication to form nanoGUMBOS directly from the ion-exchange products. This
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reaction is depicted in Figure 3.1. The synthesized nanoGUMBOS were characterized using
several techniques such as mass spectrometry, FTIR, and NMR. The presence of [BETI] and [TPB]
counter-ion peaks in the negative mode electrospray ionization mass spectrum indicates successful
ion exchange of [R6G][Cl] to form respective GUMBOS. Data for α-CD [R6G][BETI] and α -CD
[R6G][TPB] are shown in Figures 3.2 and 3.3. Similar results were obtained for all three CD
employed. FTIR and NMR of [R6G][BETI] and [R6G][TPB] showed no peak shift for the CDtemplated nanoGUMBOS suggesting that CD was only used as a template and was washed away
during synthesis. Figures 3.4 and 3.5 display the respectively the NMR and FTIR of α-CD
[R6G][BETI] and [R6G][TPB]. Similar results were obtained for all employed CDs.

Figure 3.1. Synthesis of [R6G][BETI] and [R6G][TPB] nanoGUMBOS

63

Figure 3.2. Electrospray Ionization Mass Spectrum in positive and negative mode for α-CD R6G
TPB
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Figure 3.3. Electrospray Ionization Mass Spectrum in positive and negative mode for α-CD R6G
BETI
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Figure 3.4. Overlay of NMR of [R6G][TPB] and [R6G][BETI] nanoGUMBOS with and without
CD-templating
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Figure 3.5. FTIR of [R6G][TPB] and [R6G][BETI] nanoGUMBOS with and without CDtemplating
TEM microscopy and zeta potential of the nanoGUMBOS were then investigated to assess
size and stability of the nanoparticles. Figure 3.6 and 3.7 portray TEM images of respectively
[R6G][TPB] and [R6G][BETI] nanoGUMBOS with and without CD-templating. Table 3.1
summarizes sizes for both [R6G][TPB] and [R6G][BETI] nanoGUMBOS in the presence and
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absence of CD. A significant reduction in size was observed in the presence of CD-templating for
both [R6G][TPB] and [R6G][BETI] nanoGUMBOS. These results are consistent with findings
from Hamden et al. that indicated CD-templating of nanoGUMBOS can lead to a significant
reduction in nanoparticle size.28 In addition, significantly improved polydispersity of the
synthesized nanoparticles was observed due to formation within the CD cavity.28,33
Correlation between the sizes of the nanoparticles and the CD type suggest that size of the
nanoparticle depends upon both the size of the drug and the CD cavity. Almost a 50% reduction
in nanoparticle size was observed for the HP-α-CD, and HP-β-CD [R6G][TPB] nanoGUMBOS
while a slightly larger size was observed for the γ-CD [R6G][TPB]. This difference in size can be
attributed to the relatively smaller cavity size of the α and β-CD as compared to γ-CD.33 In contrast,
while a slight variation in size was observed, all of the [R6G][BETI] CD-templated
nanoGUMBOS had relatively similar sizes around 70-80 nm. This behavior is most likely due to
the bulky aromatic rings of TPB in contrast to the relatively smaller structure of BETI. In this
regard, a larger cavity size is more likely to optimally fit the large aromatic ring structure of TPB,
resulting in a larger variation in size.

Figure 3.6. TEM images of 100 µM [R6G][TPB] nanoGUMBOS with and without CD-templating
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Figure 3.7. TEM images of 100 µM [R6G][BETI] nanoGUMBOS with and without CDtemplating
Table 3.1. Sizes of [R6G][TPB] and [R6G]BETI] nanoGUMBOS
NanoGUMBOS

Size (nm)

[R6G][TPB] Control

99 ± 16

[R6G][TPB] HP-α-CD

55 ± 5

[R6G][TPB] HP-β-CD

44 ± 4

[R6G][TPB] γ-CD

69 ± 6

[R6G][BETI] Control

92 ± 14

[R6G]BETI] HP-α-CD

68 ± 8

[R6G][BETI] HP-β-CD

66 ± 4

[R6G][BETI] γ-CD

80 ± 7

Following TEM characterization, DLS and zeta potential measurements were performed
to further understand the effect of cyclodextrin on size distribution and stability of the
nanoGUMBOS respectively. DLS measurements indicated that all synthesized nanoGUMBOS
displayed a polydispersity of 0.2; thus, indicating relatively monodispersed nanoparticles. Zeta
potential measurements were carried out in phosphate buffered saline maintained at physiological
pH (pH 7.4) to mimic the biological environment. As shown in table 3.2, while the zeta potential
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measurement for [R6G][TPB] is around -23.1 ± 1.2 mV, CD-templated nanoGUMBOS displayed
a zeta potential of around -28 mV, indicating formation of slightly more stable nanoparticles with
CD templating. Similar results were seen for [R6G][BETI] nanoGUMBOS where the zeta
potential varied from -24.3 ± 1.3 mV

to -29 mV between the control and CD-templated

nanoGUMBOS respectively. These results suggest that use of the CD-templating led to improved
stability of the nanoGUMBOS.
Table 3.2. Zeta Potential of [R6G][TPB] and [R6G]BETI] nanoGUMBOS
NanoGUMBOS
Zeta Potential (mV)
[R6G][TPB] Control

-23.1 ± 1.2

[R6G][TPB] HP-α-CD

-27.2 ± 1.5

[R6G][TPB] HP-β-CD

-29.5 ± 1.1

[R6G][TPB] γ-CD

-28.3 ± 0.9

[R6G][BETI] Control

-24.3 ± 1.2

[R6G]BETI] HP-α-CD

-29.0 ± 1.1

[R6G][BETI] HP-β-CD

-30.1 ± 0.8

[R6G][BETI] γ-CD

-29.8 ± 1.6

3.3.2. Examination of Cell Viability
NanoGUMBOS were then employed in vitro to assess the effect of this size variation on
the toxicity. Figure 3.8 is a graphical representation of the cytotoxicity of [R6G][TPB]
nanoGUMBOS with and without CD templating towards MDA-MB-231 breast cancer cells. The
IC50 values, the concentration at which 50% cell death occurs, for [R6G][TPB] nanoGUMBOS
are reported in Table 3.3. Interestingly, an enhanced cytotoxicity was observed for CD-templated
[R6G][TPB] nanoGUMBOS as compared to the nanoGUMBOS alone. In this regard, while the
[R6G][TPB] nanoGUMBOS displayed an IC50 value of 7.32 µg/mL in the absence of CD,
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templating with α and β-CD led to a three-fold reduction in IC50 value to 2.64 µg/mL and 2.77
µg/mL respectively. Templating with γ-CD led to a five-fold reduction in the IC50 to 1.41 µg/mL.
Statistical analysis indicated that the IC50 concentration of γ-CD significantly varies from that of α
and β-CD at a 95% confidence level.
Toxicity of the [R6G][BETI] nanoGUMBOS with and without cyclodextrin templating is
presented in Figure 3.9. Similar the [R6G][TPB] nanoGUMBOS, an enhanced cytotoxicity was
observed for the CD-templated [R6G][BETI] nanoGUMBOS as compared to the nanoparticles
alone. In this regard, CD-templating led to a decrease in IC50 concentration from 4.23 µg/mL for
nanoGUMBOS alone to 2.81 µg/mL for the γ-CD templated nanoGUMBOS, suggesting almost a
two-fold increase in toxicity (Table 3.4). Templating with HP-α and HP-β-CD led to an even
greater reduction in IC50 concentration to 1.45 µg/mL and 1.72 µg/mL respectively. Statistical
analysis, however, suggested that the variation in IC50 concentration with CD-cavity size was
insignificant. This indicates that in contrast to the CD-templated [R6G][TPB] nanoGUMBOS, the
toxicity of CD-templated [R6G][BETI] nanoGUMBOS was independent of CD-cavity size. In
order to further understand this contrasting behavior, toxicity of the nanoGUMBOS were then
assessed in Mia-Paca pancreatic cancer cells. Interestingly, similar results were seen for the MiaPaca pancreatic cell line, corroborating the results observed with the MDA-MB-231 cancer cells.
Remarkably, all synthesized nanoGUMBOS displayed less than 1 µg/mL IC50 values toward MiaPaca pancreatic cancer cells (Table 3.5), suggesting their promising therapeutic potential.
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Figure 3.8. Toxicity of [R6G][TPB] nanoGUMBOS with and without CD-templating towards
MDA-MB-231 breast cancer cells

Table 3.3. IC50 Concentrations of [R6G][TPB] nanoGUMBOS towards MDA-MB-231 breast
cancer cells
Compound
IC50 µg/mL
[R6G][TPB] Control

7.32 ± 1.21

[R6G][TPB] HP-α-CD

2.64 ± 0.30

[R6G][TPB] HP-β-CD

2.77 ± 0.21

[R6G][TPB] γ-CD

1.41 ± 0.24
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Figure 3.9. Toxicity of [R6G][BETI] nanoGUMBOS with and without cyclodextrin templating
towards MDA-MB-231 cancer cells

Table 3.4: IC50 Concentrations of [R6G][BETI] nanoGUMBOS towards MDA-MB-231 breast
cancer cells
Compound
IC50 µg/mL
[R6G][BETI] Control

4.23 ± 0.42

[R6G]BETI] HP-α-CD

1.45 ± 0.44

[R6G][BETI] HP-β-CD

1.72 ± 0.66

[R6G][BETI] γ-CD

2.81 ± 0.54
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Table 3.5. IC50 Concentrations of [R6G][TPB] and [R6G][BETI] nanoGUMBOS towards MiaPaca Pancreatic Cancer Cells
Compound
IC50 µg/mL
[R6G][TPB] Control

0.75 ± 0.05

[R6G][TPB] HP-α-CD

0.37 ± 0.03

[R6G][TPB] HP-β-CD

0.39 ± 0.06

[R6G][TPB] γ-CD

0.24 ± 0.04

[R6G][BETI] Control

0.45 ± 0.05

[R6G]BETI] HP-α-CD

0.21 ± 0.03

[R6G][BETI] HP-β-CD

0.25 ± 0.04

[R6G][BETI] γ-CD

0.33 ± 0.03

3.3.3 Cellular Uptake of nanoGUMBOS
In order to further understand the relationship between reduced size and enhanced toxicity
of the nanoGUMBOS, cellular uptake was examined. Figures 3.10 and 3.11 display the cellular
uptake (nmol) of 5 µM [R6G][TPB] and [R6G][BETI] nanoGUMBOS respectively after 5 h. As
shown in figure 4a, the cellular uptake of [R6G][TPB] nanoGUMBOS in the absence of CD is
significantly lower than that of the CD-templated nanoGUMBOS. Similarly, an increased cellular
uptake was also observed for the CD-templated [R6G][BETI] nanoGUMBOS as compared to the
control without CD-templating. HP-β-CD [R6G][TPB] nanoGUMBOS displayed a relatively
lower cellular uptake as compared to nanoGUMBOS templated with HP-α-CD or γ-CD.
Furthermore, in the case of the [R6G][BETI] nanoGUMBOS, all CD-templated nanoGUMBOS
displayed similar cellular uptakes, which is consistent with their relatively similar IC50
concentrations.
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Figure 3.10. Cellular uptake of 5 µM [R6G][TPB] nanoGUMBOS with and without CDtemplating in MDA-MB-231 cancer cells after 5 hrs

Figure 3.11. Cellular uptake of 5 µM [R6G][BETI] nanoGUMBOS with and without CDtemplating in MDA-MB-231 cancer cells after 5 hrs
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3.3.4. Examination of Selectivity
After detailed understanding of their behavior in cancer cells, nanoGUMBOS were
employed in Hs578Bst normal breast cells to investigate the effect of cyclodextrin on the selective
behavior of the nanomaterials. Figures 3.12 and 3.13 are graphical representations of the toxicity
of [R6G][TPB] and [R6G][BETI] with and without cyclodextrin templating towards Hs578Bst
normal breast cells. Intriguingly, the cell viability was almost 100% in normal cells for both
[R6G][TPB] and [R6G][BETI] cyclodextrin templated nanoGUMBOS, similar to the respective
controls without CD. This indicates that CD templating enhances the toxicity of the R6G
nanoGUMBOS towards cancer cells without affecting the nontoxic nature towards normal cells
under experimental conditions.

Figure 3.12. Toxicity of [R6G][TPB] nanoGUMBOS with and without CD-templating towards
Hs578Bst normal breast cells
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Figure 3.13. Toxicity of [R6G][BETI] nanoGUMBOS with and without CD-templating towards
Hs578Bst normal breast cells.
3.3.5. Optimal Size for Toxicity
Results from our studies indicate that cyclodextrin templating led to reduced size, enhanced
cellular uptake and improved cytotoxicity of the R6G nanoGUMBOS. As discussed above, a
significant reduction in IC50 was observed with the cyclodextrin templated [R6G][TPB]
nanoGUMBOS as compared to respective nanoGUMBOS without cyclodextrin. This enhanced
toxicity of the CD-templated nanoGUMBOS is consistent with the cellular uptake, which
demonstrated

increased

cellular

internalization

for

the

CD-templated

[R6G][TPB]

nanoGUMBOS. This observation is consistent with several studies which found that reduction in
size results in increased cellular uptake due to the EPR effect and variation in internalization
pathways.34-35 Furthermore, a relatively smaller cellular uptake is observed for [R6G][TPB]
nanoparticles templated with beta-CD in comparison to the γ-CD and HP-α-CD [R6G][TPB].
Correlation of the cellular uptake to the size suggests that the relatively smaller size of β-CD
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templated [R6G][TPB] nanoGUMBOS allows for rapid internalization and excretion, ultimately
leading to poor cellular retention.36
Additionally, correlation between size and cytotoxicity of both [R6G][TPB] CD-templated
nanoGUMBOS indicates an optimal size was observed for enhanced toxicity. In this regard, γ-CD
templated [R6G][TPB] nanoparticles have a size around 70 nm, while 2HP-β-CD and 2HP-α-CD
templated [R6G][TPB] nanoparticles have sizes below 60 nm. Comparison of their IC50 values
indicates that γ-CD templated nanoparticles displayed a statistically significant reduction in IC50
concentration as compared to the 2HP-β-CD and 2HP-α-CD templated nanoparticles. Moreover,
this suggests that the 70 nm nanoparticles obtained from γ-CD templating led to the most optimal
toxicity for the [R6G][TPB] nanoGUMBOS.
Similar to the [R6G][TPB] nanoGUMBOS, the CD templated [R6G][BETI]
nanoGUMBOS displayed a reduced size as compared to a control with no templating. In contrast
to the [R6G][TPB] nanoGUMBOS, however, the sizes for all the CD-templated [R6G][BETI]
nanoGUMBOS were all between 70-80 nm. In this regard, the IC50 concentrations and cellular
uptakes were relatively similar for the different CD-templated nanoGUMBOS. Thus, for the
[R6G][BETI] nanoGUMBOS, while CD-templating led to a significant reduction in IC50
concentration, no variation in IC50 concentration was with varying CD cavity size. Furthermore,
the optimal IC50 for the [R6G][TPB] nanoGUMBOS from the 70 nm γ-CD templated
nanoGUMBOS, is relatively similar to that of all the CD-templated [R6G][BETI] nanoGUMBOS.
This indicates that 70-80 nm is most likely the optimal size for improved toxicity of
nanoGUMBOS developed from R6G. It is interesting to note that while the nanoGUMBOS
without CD displayed lower or comparable toxicity to the previously reported toxicity of the parent
dye [R6G][Cl], the CD-templated nanoGUMBOS displayed an improved toxicity.21
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3.4. CONCLUSIONS
These results suggest a simple and rapid synthesis technique to control the size and
ultimately tune the cytotoxicity of nanodrugs. These studies demonstrated that CD-templated
nanoparticles display reduced size and improved stability, which can provide several benefits in
biological systems. Significantly improved in vitro toxicity was observed for [R6G][BETI] and
[R6G][TPB] CD-templated nanoGUMBOS in comparison to a control without CD. Furthermore,
γ-CD templating displayed optimal toxicity for the [R6G][TPB] nanoGUMBOS. In contrast, the
IC50 concentration was relatively similar among the different CD-templated nanoGUMBOS for
[R6G][BETI]. Moreover, the γ-CD [R6G][TPB] nanoGUMBOS and all the R6G BETI CDtemplated nanoGUMBOS displayed similar IC50 concentrations. Correlation of size and toxicity
suggests that 70-80 nm particles displayed optimal therapeutic properties for investigated R6G
nanoGUMBOS. Further examination of the nanoGUMBOS indicates no toxicity to normal breast
cells under the reported conditions giving further insight to the promising therapeutic potential of
these nanoGUMBOS. Moreover, these studies report the effect of reduced size on the toxicity of
rhodamine 6G nanoGUMBOS and the results can provide insights for similar strategies for other
chemotherapeutic nanodrugs.
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CHAPTER 4
SELECTIVE CHEMOTHERAPEUTIC APPLICATIONS OF ESTER DERIVATIVES
OF RHODAMINE (R123 AND SNAFR-5) BASED NANOGUMBOS
4.1. INTRODUCTION
Lipophilic cationic structures such as rhodamine derivatives have been widely investigated
for chemotherapeutic applications due to their hydrophobic structure and cationic properties.1-3 As
discussed in first Chapter, several studies have found that the mitochondrial membrane in cancer
cells is relatively more negative as compared to the mitochondrial membrane in normal cells.4-5 In
this regard, lipophilic cations have found to have a significantly greater accumulation in cancer
cells in contrast to normal cells, ultimately resulting in partially selective toxicity. 3, 5-6 Further
studies have shown that in addition to ionic nature, hydrophobicity also plays a major role in the
mitochondrial accumulation.7-8 Intriguingly, the hydrophobicity of rhodamine 123 is found to be
optimal for this partially selective behavior in contrast to other triarylmethane dyes such as ethyl
violet.2, 8-10
In this regard, several studies have shown that R123 demonstrates promising in vitro and
in vivo therapeutic efficacy.11-14 R123 displayed a significant in vitro toxicity towards several
pancreatic and breast cancer cell lines with no toxicity towards normal cells at low concentrations
(10 µg/mL), suggesting its partially selective behvaior.12-13 In vivo studies of R123 revealed a
significant reduction in tumor volume, suggesting its great therapeutic efficacy.15-16 Interestingly,
R123 was also employed in clinical trials for prostate cancer due to its high retention in prostate
tissue; however, a poor therapeutic efficacy was observed for the dye. Studies revealed that while
the R123 was able to inhibit doubling time for prostate-specific antigen, these results were not
statistically significant against a control that measured the doubling time in the absence of R123.17
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Moreover, these results indicate that while R123 has shown promising properties in-vitro and invivo, clinical applications of the dye did not corroborate these results.
Nanomaterials have been widely investigated for enhanced selectivity as well as enhanced
retention in tumor tissue.18-20 Furthermore, due to their interaction with the phospholipid bilayer,
nanomaterials typically internalize via active transport pathways such as endocytosis in contrast
to free dye internalization through passive diffusion.21 In regards to the poor clinical toxicity of
the R123 moiety, formation of nanomaterials can possibly lead to enhanced toxicity due to this
varied internalization. In addition, synthesis of nanomaterials can lead to a more targeted therapy
for minimized systemic toxicity of the drug.
Our research group has developed nanomaterials, nanoGUMBOS, based on rhodamine 6G
(R6G) for selective chemotherapeutic applications.22 These nanoGUMBOS are a nanoparticle
assembly of the drug itself; thus, they can be synthesized without any matrix.23 As indicated in
Magut et al., synthesis of GUMBOS from R6G led to tunable hydrophobicity, and toxicity.22 The
tunable hydrophobicity can enhance the hydrophobic interaction with the cell membrane for dyes
such as R123. In contrast to the studies investigated by Belostotsky et al. that suggested the major
role of hydrophobicity plays in the selective accumulation, GUMBOS provide a rapid interface to
tune the hydrophobicity of a single cation rather than examine several cations.8, 22-23
In the studies presented, GUMBOS derived from two rhodamine derivatives, R123 and
Seminapthofluorone-5 (SNAFR-5), containing an ester structure similar to that of R6G were
examined for selective chemotherapeutic behavior that was observed with the R6G
nanoGUMBOS. Relative hydrophobicity of the GUMBOS was characterized using octanol-water
partition coefficients. Subsequently, the nanoGUMBOS were employed in-vitro in MDA-MB-231
cancer cells to examine their cellular uptake and therapeutic potential. Lastly, the nanoGUMBOS
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were employed in Hs578Bst normal cells to examine if these GUMBOS also displayed the
selective chemotherapeutic behavior observed with the R6G nanoGUMBOS. These studies
provide further insight to an approach for rapid synthesis of selective nanomaterials from cationic
drugs in order to minimize their systemic toxicity.
4.2. MATERIALS AND METHODS
4.2.1. Materials
Rhodamine 123, phosphate buffered saline (10x concentrate, 0.2 uM filtered), sodium
tetraphenylborate [Na][TPB], dicholromethane (DCM), dimethylsulfoxide (DMSO), and 1octanol

were

purchased

from

Sigma-Aldrich

(Milwaukee,

WI).

Lithium

bis

(perfluoroethylsulfonyl) imide [Li][BETI] was obtained from Ionic Liquid Technologies
(Tuscaloosa, Al). SNAFR-5 was obtained from Dr. Robert Strongin (Portland, OR). Triply
deionized water was obtained from an Aires High Purity Water System (Port Allen, LA). The cell
viability MTT (3-[4, 5-Dimethylthiazol-2-yl]-2, 5-diphenyltetrazolium bromide) assay was
purchased from Promega Corporation (Madison, WI). TEM (copper) grids were purchased from
Ted Pella (Redding, CA).
4.2.2. Synthesis of Rhodamine-based GUMBOS
The rhodamine-based GUMBOS were synthesized using a biphasic ion-exchange reaction.
Briefly, a DCM solution of [R123][Cl] was mixed with aqueous [Li][BETI] or [Na][TPB] at a
1:1.2 molar ratio. This biphasic mixture was allowed to stir for 48 h at room temperature.
Subsequently, the water layer was removed, and the DCM layer was washed with deionized water
to remove any traces amount of [Li][Cl] or [Na][Cl]. The DCM layer was then evaporated and the
product was dried in vacuo for 24 h to obtain the final product. The synthesized GUMBOS were

85

characterized using electrospray ionization (ESI) mass spectrometry. A similar protocol was
employed for synthesis of the SNAFR-5 based GUMBOS as well.
4.2.3. Synthesis of Rhodamine-based nanoGUMBOS
The rhodamine-based nanoGUMBOS were synthesized using a reprecipitation method.
Briefly, the GUMBOS were dissolved in a small amount of DMSO and a small amount of this
solution was rapidly injected in cell media under ultrasonication for five minutes to make a 1 mM
solution of nanoGUMBOS. Subsequently the nanoparticles were allowed to grow for 30 minutes.
The obtained nanoparticles were further diluted to the working concentration for characterization
and cell studies.
4.2.4. Characterization of the nanoGUMBOS
The nanoGUMBOS were characterized using TEM, DLS and zeta potential measurements.
For the TEM, the 5 µL of a 100 µM solution was spotted on a TEM grid and allowed to dry
overnight. For DLS and Zeta potential measurements, the 1 mM solution of nanoGUMBOS was
centrifuged, and then dried in-vacuo. The resulting pellet was then resuspended in phosphate
buffered saline to make a 12 µM solution of nanoGUMBOS.
4.2.5. Octanol-Water Partition Coefficients
A 1:1 volume ratio of octanol and water was stirred overnight. The water and octanol layer
were then separated. The octanol layer was then used to generate a calibration curve from the
absorbance of the compound at various concentrations. A known concentration (Ci) was chosen
from the calibration curve and an equivalent volume of water was then added to the octanol layer
and this mixture was stirred for 24 h. The absorbance of the octanol layer was determined. The
calibration curve generated in octanol was then used to calculate the compound in octanol (Co).
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The concentration of dye in the water (Cw) was then calculated using the formula 𝐶𝑖 − 𝐶𝑜 = 𝐶𝑤 .
The octanol water partition coefficient (Kow) was then calculated using the formula 𝐾𝑜𝑤 = 𝐶𝑓 /𝐶𝑤
4.2.6. Cell Culture
Hormone independent human breast adenocarinoma (MDA-MB-231) and normal human
breast fibroblast (Hs578Bst) were all purchased from the American Tissue Culture Collection
(ATCC, Manassas, VA). Cell lines were cultured to 90% confluence according to ATCC protocol
prior to experimentation.
4.2.7. Cytotoxicity Measurements
A 96 well plate was incubated with 5000 cells/well for 24 h. Subsequently, a 1 mM solution
of the nanoGUMBOS was synthesized and diluted to 100 µM. The cells were then treated with 0–
100 µM of the nanoGUMBOS and incubated for another 48 h. Each compound was tested in
triplicates to obtain a standard deviation. Following the 48 h incubation, an MTT assay was
performed to determine cytotoxicity. First, 15 µL of the MTT dye was incubated into the cells for
3 h. Then, the cells were treated with 100 µL of the stop solution and incubated for another 1 h.
The absorbance of the 96 well plate was measured at 570 nm using a microplate
spectrophotometer. The cell viability is reported as a percentage of the ratio of experimental cells
to an untreated control normalized to 100% cell viability. All plates were performed in triplets to
obtain a standard deviation, and reported cell viabilities represent the average of these
measurements.
4.2.8. Cellular Uptake Studies
For the cellular uptake studies 35 mM petri dishes were seeded with 20,000 cells per petri
dish for 24 h. Following the 24 h. incubation, the cells were then treated with a 50 µM solution of
nanoGUMBOS and incubated for 1 h. to allow the nanoGUMBOS to internalize. One petri dish
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was only treated with cell media and served as a control. After 1 h, the cell media was removed
and any nanoGUMBOS not internalized by the cell were washed away using PBS buffer.
Subsequently, 3 mL of DMSO was incubated for 5 h. to lyse the cells open. The absorbance of the
DMSO solution was then measured using the untreated control cells as the reference cell.
Calibration curves for each of the nanoGUMBOS was made by taking the absorbance of at 1, 2,
4, 6, and 10 µM in DMSO. The calibration curve was then used to calculate the concentration
nanoGUMBOS in the DMSO used to treat the cells, this concentration was recorded as internalized
concentration. The cellular uptake of the compound was calculated in nanomoles of compound
internalized. All measurements were carried out in triplicate to obtain standard error.
4.3. RESULTS AND DISCUSSIONS
4.3.1. Characterization of GUMBOS and nanoGUMBOS
Four GUMBOS ([R123][BETI], [R123][TPB], [SNAFR][BETI], and [SNAFR][TPB])
were synthesized using a simple metathesis reaction depicted in Figure 4.1. GUMBOS were
characterized using electrospray mass spectrometry to confirm the presence of the desired counterion (Table 4.1). Following synthesis of the GUMBOS, hydrophobicity was examined using octanol
water partition coefficients (Kow). The GUMBOS showed varied hydrophobicity based on cation
variation. Table 4.2 presents the log Kow for the parent dyes as well as the GUMBOS. Examination
of the log Kow for the parent dyes indicates that, for a constant cation and varying anions, the
hydrophobicity trend beginning with the most hydrophobic compound is [R123][BETI] ˃
[R123][TPB] ˃ [R123][Cl]. A similar trend was observed with the SNAFR based GUMBOS as
well. Furthermore, for both of the GUMBOS, the BETI anion remained the most hydrophobic.
These results suggest that counter-ion variation of the R123 salts led to varying hydrophobicity of
the resulting GUMBOS.
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Figure 4.1. Synthesis of R123 and SNAFR-5 GUMBOS
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Table 4.1. Results from ESI mass spectrometry characterization of GUMBOS
Compound
Positive Mode
Negative Mode
Theoretical
Mass

Actual

Theoretical

Actual

Mass

Mass

Mass

[R123][BETI]

345.4

345.6

381.1

381.4

[R123][TPB]

345.4

345.5

319.3

319.2

[SNAFR-5][BETI]

458.3

458.2

381.1

381.2

[SNAFR-5][TPB]

458.3

458.2

319.3

319.1

Table 4.2. Relative hydrophobicity of R123 and SNAFR-5 based GUMBOS
Compound

Log Kow

[R123][BETI]

1.10 ± 0.22

[R123][TPB]

0.80 ± 0.28

[R123][Cl]

0.25 ± 0.05

[SNAFR-5][BETI]

1.40 ± 0.25

[SNAFR-5][TPB]

1.20 ± 0.16

[SNAFR-5][OH]

0.28 ± 0.04

Following examination of the hydrophobicity of the GUMBOS, nanoGUMBOS were
synthesized using a simple reprecipitaiton method described in the experimental section. TEM
images in Figure 4.2 display spherical nanoparticles with a size around 100 nm for both R123 and
SNAFR based nanoGUMBOS. Table 4.3 presents the zeta potential of the R123 and SNAFR
GUMBOS at physiological pH (7.4). As shown in table 4.3, zeta potentials for the R123 and
SNAFR nanoGUMBOS are around –17 mV which suggests formation of relatively stable
nanomaterials. Nanoparticles displayed a polydispersity below 0.2 when subjected to dynamic
light scattering (DLS), indicating formation of relatively monodispersed nanoparticles.
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Table 4.3. Zeta potential of R123 and SNAFR-5 nanoGUMBOS
NanoGUMBOS

Zeta Potential (mV)

[R123][BETI]

-16.8 ± 1.1

[R123][TPB]

-16.5 ± 1.4

[SNAFR-5][BETI]

-17.4 ± 0.8

[SNAFR-5][TPB]

-16.9 ± 1.3

Figure 4.2. TEM images of R123 and SNAFR-5 nanoGUMBOS
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4.3.2. Spectroscopic Studies
Following synthesis and characterization of GUMBOS and nanoGUMBOS, spectroscopic
studies were performed to examine the optical behavior of the new materials. As indicated in
Figure 4.3, no shift in absorbance and fluorescence emission peak maxima were observed for
between the R123 GUMBOS and the parent dye [R123][Cl]. Formation of R123 nanoGUMBOS
in water led to a slight 10 nm blue shift; however, no peak shift was observed between the
nanoGUMBOS and the parent dye in water (Figure 4.4). Examination of the absorbance and
fluorescence emission of the SNAFR-5 based GUMBOS presented in Figure 4.5 indicates no peak
shift following formation of the GUMBOS, similar to the R123 based GUMBOS described earlier.
Interestingly, a significant peak shift was observed between [SNAFR][TPB] nanoGUMBOS and
the parent dye, while no peak shift was observed for the [SNAFR][BETI] nanoGUMBOS. In this
regard, the absorbance of [SNAFR][BETI] nanoGUMBOS and [SNAFR][OH] parent dye
displayed blue shifting in water as compared to their absorbance in DMSO. In contrast, the
absorbance of [SNAFR][TPB] nanoGUMBOS was further red shifted in water in comparison to
its absorbance in DMSO. Examination of the fluorescence emission presented in Figure 4.6
suggests a significantly diminished fluorescence intensity for [SNAFR][TPB] in comparison to
[SNAFR][BETI] and [SNAFR][OH]. This could possibly be due to J-aggregation of [R6G][TPB]
nanoGUMBOS as indicated by the red-shifted absorbance.24 In addition, the longer wavelength of
the [SNAFR][TPB] nanoGUMBOS in contrast to typical rhodamines suggests that these
nanoparticles have suitable properties to act as a photosensitizer dye for photodynamic therapy
applications.25
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Figure 4.3. Absorbance and fluorescence of R123 based GUMBOS in DMSO

Figure 4.4. Absorbance and fluorescence of R123 based nanoGUMBOS in water
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Figure 4.5. Absorbance and fluorescence of SNAFR-5 based GUMBOS in DMSO

Figure 4.6. Absorbance and fluorescence of SNAFR-5 based nanoGUMBOS in PBS buffer
4.3.3. Examination of Toxicity
These compounds were then employed in MDA-MB-231 breast cancer cells to examine
their chemotherapeutic properties. Figures 4.7 and 4.8 are graphical representation of the toxicity
of the R123 and SNAFR-5 based nanoGUMBOS towards MDA-MB-231 breast cancer cells
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respectively. R123 nanoGUMBOS display similar toxicity to that of the parent dye [R123][Cl] as
shown in Figure 4.7. [R123][TPB] and [R123][BETI] displayed IC50 concentrations of 17.41 and
20.62 µM, which are relatively similar to the IC50 concentration of [R123][Cl], 24.32 µM. While
the IC50 values for the R123 nanoGUMBOS are slightly lower than that of parent dye, statistical
analysis indicate no significant difference between the concentrations. [SNAFR-5][BETI] and
[SNAFR-5][TPB] displayed IC50 concentrations of 8.75 µM and 12.22 µM respectively, while the
parent dye [SNAFR-5][OH] displayed an IC50 concentration of 1.31 µM. These results indicate
that formation of SNAFR based nanoGUMBOS led to decreased toxicity in comparison with the
parent dye.

Figure 4.7. Toxicity of R123 nanoGUMBOS towards MDA-MB-231 cancer cells
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Figure 4.8. Toxicity of SNAFR-5 nanoGUMBOS towards MDA-MB-231 cancer cells
Figure 4.9 presents the cellular uptake of the R123 and SNAFR nanoGUMBOS in MDAMB-231 breast cancer cells after 5 h. incubation. The R123-based nanoGUMBOS displayed
cellular uptake comparable to that of the parent dye [R123][Cl]. This is consistent with the toxicity
results that showed similar IC50 concentrations between the R123 nanoGUMBOS and the parent
dye. In contrast, SNAFR-5 based nanoGUMBOS displayed a significantly lower than that of the
parent dye. This further corroborates the decreased toxicity for the nanoGUMBOS in comparison
with the parent dyes.
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Figure 4.9. Cellular Uptake of R123 and SNAFR-5 nanoGUMBOS
Toxicity of the GUMBOS towards MCF7 breast cancer and MiaPaca pancreatic cancer
cells was also evaluated. Table 4.4 compares the IC50 of R123 and SNAFR-5 based nanoGUMBOS
towards MDA-MB-231, MCF7 and Mia-Paca cancer cell lines. While the R123 compounds
displayed IC50 concentrations of 17-25 µM and 1-3 µM for the MDA-MB-231 and MiaPaca cell
lines respectively, they displayed an IC50 above 100 µM for the MCF7 cancer cells. These
examinations indicated that that the toxicity of the nanoGUMBOS is greater towards the more
aggressive MDA-MB-231 and Mia Paca cancer cells in contrast to the less aggressive MCF7
cancer cell line. Similar results were seen for the SNAFR-5 based nanoGUMBOS as well.
However, in contrast to the R123 compounds, the overall toxicity of the SNAFR-5 was found to
be greater. It is interesting to note that the SNAFR-5 based nanoGUMBOS displayed less than 1
µM IC50 concentrations towards MiaPaca cancer cells, suggesting their great therapeutic potential.
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Table 4.4. IC50 values for R123 and SNAFR-5 based nanoGUMBOS towards MDA-MB-231,
MiaPaca and MCF7 cancer cell lines
MDA-MB-231
MiaPaca
MCF7
IC50 (µM)

IC50 (µM)

IC50 (µM)

[R123][BETI]

17.41 ± 3.73

1.61 ± 0.72

˃100

[R123][TPB]

20.62 ± 3.51

2.52 ± 0.94

˃100

[R123][Cl]

24.32 ± 2.24

3.15 ± 1.12

˃100

[SNAFR-5][BETI]

8.75 ± 1.86

0.66 ± 0.03

32.50 ± 1.12

[SNAFR-5][TPB]

12.22 ± 2.90

0.72 ± 0.02

26.75 ± 2.26

[SNAFR-5]

1.31 ± 0.52

0.13 ± 0.02

3.71 ± 0.71

Following application in cancer cell lines, these nanoGUMBOS were also employed in
Hs578Bst normal breast cells. Figures 4.10 and 4.11 display the toxicity of the R123 and SNAFR5 based nanoGUMBOS, respectively towards Hs578Bst normal breast cells. Intriguingly, while
both of the parent dyes [R123][Cl] and [SNAFR-5][OH] displayed slight toxicity towards normal
cells, formation of the nanoGUMBOS led to completely selective behavior under investigated
conditions. Furthermore, both the parent dyes displayed a higher IC50 for normal cells as compared
to cancer cells. This partially selective behavior is consistent with findings from Belostotsky et al.
that lipophilic rhodamine cations have enhanced cellular uptake in cancer cells as compared to
normal cells due to their electrostatic interaction with the negative cell membrane.8 Furthermore,
the selective behavior of the nanoGUMBOS most likely resulted from use of energy dependent
pathways in contrast to diffusion. While both SNAFR and R123 are relatively soluble in water and
can use diffusion to internalize, the nanoGUMBOS most likely use active transport for
internalization; thus, this variation in internalization pathway, similar to that observed in Chapter
2 of this dissertation, is a possible explanation for the selective chemotherapeutic behavior of the
SNAFR and R123 nanoGUMBOS.
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Figure 4.10. Toxicity of R123 nanoGUMBOS towards Hs578Bst normal cells

Figure 4.11. Toxicity of SNAFR-5 nanoGUMBOS towards Hs578Bst normal cells
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4.4. CONCLUSIONS
These results present an approach to develop tunable nanomaterials that display selective
toxicity towards cancer cells with minimal effect to normal cells. Synthesis of GUMBOS led to
enhanced hydrophobicity in comparison to the respective parent dyes. This increased
hydrophobicity led to nanoparticle formation in aqueous medium. These nanoGUMBOS
demonstrated promising in vitro toxicity towards both breast and pancreatic cancer cells.
Remarkably, no toxicity towards normal cells under experimental conditions were observed. This
selective behavior is of great interest to reduce the numerous side-effects of current
chemotherapeutics. Interestingly, evaluation of the nanoGUMBOS toxicity towards multiple cell
lines suggested greater efficacy towards the more aggressive cell lines. Evaluation of the optical
properties of these nanoGUMBOS indicates that in addition to employment as chemotherapeutics,
the synthesized nanoGUMBOS also display strong cellular imaging potential. Moreover, these
results give further insight to rapid development of selective chemotherapeutic nanomaterials for
chemotherapy and tumor imaging applications.
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CHAPTER 5
CHEMOTHERAPEUTIC APPLICATIONS OF CARBOXYLIC ACID BEARING
RHODAMINE BASED GUMBOS AND NANOGUMBOS
5.1 INTRODUCTION
In addition to the R123 dye discussed in Chapter 4, rhodamine 110 (R110) and rhodamine
B (RB) have also been investigated for chemotherapeutic and in-vitro imaging applications.1-3
Several studies have compared the in-vitro imaging of the zwitterion R110 and the cation R123 in
order to understand the relevance of structure and charge on cellular uptake. Interestingly, while
R110 suffers from poor cellular uptake, R123 exhibits promising in vitro chemotherapeutic
imaging properties.4-5 In this regard, the cationic charge of R123 enables a strong electrostatic
interaction with the negative cell membrane, while the zwitterion structures of RB and R110 hinder
this interaction. This hindered interaction between these zwitterion dyes with the cell membrane
ultimately leads to reduced internalization, limiting their biomedical applications.5
Further studies have demonstrated cellular internalization of R110 and RB in their
protonated acid form; however, the acid-base properties of the carboxylic acid functional group
limit their therapeutic and imaging potential. As discussed in Chapter 1, rhodamine dyes
preferentially accumulate in the mitochondria and block ATP production, causing cellular
apoptosis. However, the carboxylic acid functional group of RB and R110 causes a reduction in
mitochondrial pH, leading to minimal mitochondrial accumulation and decreased therapeutic
potential.2,

6

Thus, while cationic dyes such as R123 serve as strong imaging agents for the

mitochondria, the zwitterion structure of RB and R110 deters their imaging applications.
Nanocarrier systems such as liposomes, polymers and micelles have been investigated as
intracellular delivery systems to enhance the internalization of hydrophobic drugs. 7-10 This
increased cellular uptake is typically due to the nanoscale size of the nanoparticle that allows for
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rapid permeation into the cell.11-12 Additionally, several studies have also demonstrated that
endocytic internalization of nanoparticles can be exploited for selective toxicity towards cancer
cells with minimal toxicity towards normal cells.13-15 Our research group has developed
nanoGUMBOS, i.e. nanomaterials derived from a group of uniform materials based on organic
salts (GUMBOS), that displayed selective chemotherapeutic properites.16 As discussed in Chapter
1, synthesis of nanoGUMBOS from rhodamine 6G, a lipophilic cation with known anticancer
properties, led to selective chemotherapeutic toxicity of the resulting nanomaterials under
examined conditions.17 In contrast to the existing nanocarrier systems that typically consist of
liposomes and polymers, nanoGUMBOS give distinct advantages such as ease of synthesis, as
well as tunable toxicity. Intriguingly, nanoGUMBOS serve as the drug themselves eliminating the
need for detailed characterization of drug loading and release profiles.18-20 However, since the
nanoGUMBOS is developed from the dye itself, the zwitterion structure of the RB and R110 may
affect the surface charge of the nanomaterials, ultimately affecting their therapeutic properties.21
In this regard, the tunable nature of GUMBOS allows for modification of several properties
through counter-ion variation.16, 22 Typical GUMBOS consist of cation and anion moieties, but the
zwitterion structure of RB and R110 dyes allows for addition of a secondary cation at physiological
pH resulting in a triple GUMBOS structure. This allows for a simple synthetic route to modify the
overall charge of the resulting compounds. Furthermore, if the secondary cation chosen has
anticancer properties then the developed nanodrug possesses dual therapeutic properties.
Moreover, this allows for innovative combinations of multiple anticancer compounds into a novel
nanoparticle.
Herein, we report the in vitro therapeutic properties of the GUMBOS derived from RB and
R110. GUMBOS were synthesized through counter-ion variation using the tetraphenylborate
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(TPB) and lithium bis(perfluoroethylsulfonyl)imide (BETI) anions investigated in the previous
chapters. Addition of a secondary cation to the zwitterion structure of these dyes was also explored
to synthesize a triple nanoGUMBOS. The effect of counter-ion variation on the hydrophobicity
was examined using octanol-water partition coefficients. Subsequently, toxicity and cellular
uptake of the nanoGUMBOS was examined in MDA-MB-231 cancer cells to assess their
therapeutic potential. Lastly, toxicity of the nanoGUMBOS was examined in Hs578Bst normal
breast cells to study the effect of counter-ion variation and modification of the carboxylic acid
structure on the selective behavior of the nanoGUMBOS. Furthermore, these results give further
insight to a method to improve the cytotoxic behavior and imaging properties of zwitterion dyes.
5.2. MATERIALS AND METHODS
5.2.1. Materials
Rhodamine B chloride, rhodamine 110 chloride, phosphate buffered saline (10x
concentrate, 0.2 µM filtered), sodium tetraphenylborate [Na][TPB], dichloromethane (DCM),
dimethylsulfoxide (DMSO), 1-octanol, sodium hydroxide (NaOH), citric acid monohydrate, and
sodium phosphate dibasic were purchased from Sigma-Aldrich (Milwaukee, WI). Lithium
bis(perfluoroethylsulfonyl)imide ([Li][BETI]) was obtained from Ionic Liquid Technologies
(Tuscaloosa, Al). Triply deionized water was obtained from an Aires High Purity Water System
(Port Allen, LA). The MTT (3-[4, 5-Dimethylthiazol-2-yl]-2, 5-diphenyltetrazolium bromide) cell
viability assay was purchased from Promega Corporation (Madison, WI). TEM grids were
purchased from Ted Pella (Redding, CA).
5.2.2. Synthesis of GUMBOS
All GUMBOS were synthesized via a one phase reaction scheme. Briefly, the rhodamine
dye and the desired counter ion, either [Li][BETI] or [Na][TPB], were dissolved in a pH 3 citric
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acid phosphate buffer, and the solution was stirred for 15 minutes. Subsequently, the pink
precipitate was centrifuged multiple times while washing the in between with citric acid phosphate
buffer to remove any byproduct. The product was then dried in vacuo.
5.2.3. Synthesis of Triple GUMBOS
Triple GUMBOS were synthesized via a biphasic metathesis reaction modified from
literature.23 Firstly, [R110][Cl] or [RB][Cl] was dissolved in water with an equimolar
concentration of sodium hydroxide (NaOH). Subsequently, this aqueous solution was mixed with
a DCM solution containing either [R6G][Cl] or [P4444][Br], and this biphasic mixture was
allowed to stir for 24 h. Completion of the ion exchange was indicated by a transfer of the
rhodamine pink color from the aqueous layer to the DCM organic layer. The clear aqueous layer
was then removed and an aqueous solution containing [Na][TPB] was then added to the organic
layer, and this biphasic mixture was stirred for 48 h. The aqueous layer was separated from DCM
layer and washed with water several times to remove any byproduct. The DCM was then
evaporated and the product was dried in vacuo to obtain a pink powder.
5.2.4. Synthesis of nanoGUMBOS
NanoGUMBOS were synthesized using a reprecipitation method. A DMSO solution
containing GUMBOS was rapidly injected into cell media under ultrasonication at a 2% volume
ratio between DMSO and cell media. NanoGUMBOS were allowed to grow for 30 minutes, and
then the solution was diluted to 100 µM for TEM characterization and cell studies.
5.2.5. Octanol Buffer Partition Coefficients
In 20 ml vial, 1-Octanol is mixed with a pH 7.4 phosphate-citric acid buffer and stirred
overnight. The two layers were separated and then a calibration curve is generated for each
compound in 1-octanol at various concentrations. The phosphate-citric acid buffer is then added to
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one of the concentrations (Ci) and this mixture is stirred for 48 h. Subsequently, the absorbance in
the octanol layer was measured and the concentration (Co) was calculated using the calibration
curves. Later, the equation (𝐶i − 𝐶o = 𝐶w ) was used to calculate the concentration in water (Cw).
The octanol water partition coefficient was then calculated using the equation 𝐾ow = 𝐶f /𝐶w .
5.2.6. Solubility Studies
Approximately fifty milliliters of water was added to three milligrams of GUMBOS.
Absorbance measurements were then taken over time until the absorbance reached a plateau. A
calibration curve in water was then generated for the GUMBOS at a soluble concentration, and the
generated equation was used to calculate the solubility concentration. The solubility constant (Ksp)
is then calculated from the solubility concentration.
5.2.7. Spectroscopic Studies
Spectroscopic studies for all GUMBOS were preformed using a 5 µM solution of
GUMBOS in either DMSO or PBS Buffer. A reprecipitaiton method was used to synthesize the
triple nanoGUMBOS for these studies. Briefly, a 1 mM solution of the triple GUMBOS in DMSO
was reprecipitated under ultrasonication in phosphate buffered saline (2% DMSO/buffer ratio) for
five minutes and aged for another 30 minutes to synthesize a 5 µM of nanoGUMBOS. All
nanoGUMBOS were sonicated for 1 minute before analysis to ensure a homogenous mixture.
5.2.8. Cell Culture
Hormone independent breast adenocarcinoma (MDA-MB-231), hormone dependent breast
adenocarcinoma (MCF7), human pancreatic carcinoma (Mia-Paca), and normal human fibroblast
cell lines were purchased from the American Tissue Culture Collection (ATCC, Manassas, VA).
Cell lines were cultured to 90% confluence using the ATTC guidelines for cell culture prior to
experimentation.
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5.2.9. Cell Viability Studies
A 96 well plate was seeded with 5000 cells/well and incubated for 24 h to allow them to
attach. A serial dilution from 100 µM to 0 µM was performed for each compound. The compounds
were then incubated into the cells for 48 h and subsequently an MTT assay was performed to
determine the cell viability. Firstly, 15 µL of the MTT dye solution wa incubated in the cells for 3
h. This MTT dye reacts with NADPH present in live cells to form an insoluble purple formazan
product. Subsequently, 100 µL of the stop solution was added to solubilize this product, ending
the enzymatic reaction between the NADPH and the MTT dye. The cells were incubated with the
stop solution for 1 h. Subsequently, the absorbance of the formazan is then measured at 570 nm
using a microplate spectrophotometer. Cell viability is reported as the percentage of the ratio
between experimental groups and a control normalized to 100%. All measurements were
performed in triplicate measurements to obtain standard error, and the reported cell viability is the
average of these measurements.
5.2.10. Cellular Uptake
For the cellular uptake studies, 200,000 cells were seeded in a 35 mm petri dish and the
cells were incubated at 37 °C overnight. The cells were then incubated with a 12.5 µM solution of
nanoGUMBOS for 5 h. An untreated control containing no drug was used as a reference.
Subsequently, the nanoGUMBOS solution was removed and the cells were incubated with 3 mL
of DMSO for 5 h. until no cells were visually present under the microscope. The absorbance of
the DMSO solution was then measured using the untreated control as a reference. A calibration
curve was generated from a set of standards for each GUMBOS ranging from 1-10 µM. The
cellular uptake was then calculated as the nmoles of compound internalized.
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5.2.11. Microscopy
Briefly, 10,000 MDA-MB-231 cancer cells were seeded onto a 35 mm glass bottom petri
dish and incubated overnight at 37 °C. Then, 20 nM of mitotracker was incubated into the cells for
30 minutes. Subsequently, a 25 nM nanoGUMBOS solution was incubated in the cells for 30
minutes. Finally, the cells were washed several times with buffer and were imaged using a 40X
dipping objective on a Leica Brightfield Microscope. A FITC filter was used to measure the
fluorescence of the mitotracker green and the TRITC filter was used to measure fluorescence of
the nanoGUMBOS.
5.3. RESULTS AND DISCUSSIONS
5.3.1 Synthesis and characterization GUMBOS
RB and R110 based GUMBOS were synthesized using a one phase reaction scheme
depicted in Figure 5.1. Characterization of the GUMBOS using electrospray mass spectrometry
confirmed the presence of the desired counter-ion, indicating successful ion exchange has occurred
(Table 5.1). Hydrophobicity of all the synthesized GUMBOS were characterized using octanolwater partition coefficients (Kow), and data is presented in Table 5.2 The hydrophobicity trend for
the RB GUMBOS from most hydrophobic to most hydrophillic is [RB][TPB] ˃ [RB][BETI] ˃
[RB][Cl]. Interestingly, a similar hydrophobicity trend is seen for R110 based GUMBOS as well.
These results demonstrate that these GUMBOS display tunable hydrophobicity through counterion variation, similar to the results presented in Magut et al. and Chapter 4 of this dissertation.17
As discussed in previous chapters, GUMBOS are typically insoluble in water and enable
the formation of a nanoGUMBOS suspension in aqueous medium. However, contrastingly from
the R123 and SNAFR-5 GUMBOS investigated in Chapter 4, no distinct nanoparticles were
observed for the RB and R110 GUMBOS. Thus, in order to further understand the lack of
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nanoparticle formation, the water solubility of RB and R110 GUMBOS was examined at
physiological pH. As shown in Table 5.3, the water solubility of GUMBOS is significantly lower
than that of the parent dyes. This is consistent with the increase in hydrophobicity observed for the
GUMBOS with respect to the parent dyes. However, RB and R110 GUMBOS displayed a
significantly higher water solubility than that of the [R6G][BETI] and [R6G][TPB] GUMBOS
which were found to make nanoGUMBOS in Magut et al.17 Rather, the water solubility for these
zwitterion GUMBOS is relatively similar to the reported more hydrophilic GUMBOS.17 In this
regard, Magut et al. reported that nanoparticles were fabricated only from the more hydrophobic
[R6G][BETI] and [R6G][TPB] GUMBOS. Thus, lack of nanoparticle formation can be attributed
to the relatively high water solubility of GUMBOS.
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Figure 5.1. Synthesis of RB and R110 GUMBOS
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Table 5.1. ESI characterization of RB and R110 GUMBOS
Compound
Positive Mode

Negative Mode

Theoretical

Actual

Theoretical

Actual

Mass

Mass

Mass

Mass

(m/z)

(m/z)

(m/z)

(m/z)

[RB][TPB]

444.2

444.4

319.3

319.5

[RB][BETI]

444.2

44.43

381.1

381.3

[R110][TPB]

331.8

331.9

319.3

319.4

[R110][BETI]

331.8

331.7

381.1

381.4

Table 5.2. Relative hydrophobicity of RB and R110 GUMBOS
Compound
Log Kow
[RB][BETI]

1.40 ± 0.14

[RB][TPB]

1.25 ± 0.21

[RB][Cl]

1.10 ± 0.18

[R110][BETI]

0.30 ± 0.04

[R110][TPB]

0.32 ± 0.03

[R110][Cl]

0.22 ± 0.04

Table 5.3. Water solubility of RB and R110 GUMBOS
Solubility
Compound
(mol/L)

Dissociation Constant
(mol2/L2)

[RB][BETI]

1.7 x 10-5

1.7 x 10-10

[RB][TPB]

1.3 x 10-5

2.9 x 10-10

[RB][Cl]

3.1 x 10-2

9.8 x 10-4

[R110][BETI]

4.1 x 10-5

7.8 x 10-10

[R110][TPB]

2.8 x 10-5

1.7 x 10-10

[R110][Cl]

˃ 7.0 x 10-4

˃ 4.6 x 10-7
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5.3.2. Spectroscopic Studies of RB and R110 based GUMBOS
Absorbance and fluorescence behavior of the GUMBOS was then investigated to assess
any variation in photophysical properties. Absorbance and fluorescence spectra of GUMBOS in
DMSO displayed no apparent shift in absorbance or fluorescence emission maxima as compared
to the parent dyes (Figures 5.2 and 5.3). RB GUMBOS displayed a peak absorbance at 540 nm
and peak emission at 570 nm in DMSO, which corresponds to the peaks for [RB][Cl]. Similarly,
R110 GUMBOS displayed a peak absorbance at 510 nm and peak emission at 538 nm,
corresponding to the peaks for [R110][Cl]. The fluorescence emission intensity of [RB][TPB] and
[RB][BETI] both are comparable to the parent dye [RB][Cl]. However, a decrease in fluorescence
intensity was observed for R110 based GUMBOS with respect to the parent dye. These results
suggest that in addition to the hydrophobicity and solubility, optical properties of the GUMBOS
can also be tuned via counter-ion variation.
After examination of GUMBOS in DMSO, the optical behavior of nanoGUMBOS in PBS
buffer was also investigated to mimic the biological environment. As shown in Figures 5.4 and
5.5, a 5 nm blue shift was observed for the R110 compounds in water, whereas a 10 nm red shift
was observed for the RB compounds. Absorbance peak maxima for all the GUMBOS in water
were consistent with respective parent dyes suggesting that the shift is due to solvent polarity.
Furthermore, both RB and R110 GUMBOS displayed substantial fluorescence emission,
indicating their possible use as probes for fluorescence guided surgery in addition to their
chemotherapeutic application. In this regard, these dyes can aid in tumor imaging while also
eradicating any unresected tumor tissue.
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Figure 5.2. Absorbance and Fluorescence of RB GUMBOS in DMSO

Figure 5.3. Absorbance and Fluorescence of R110 GUMBOS in DMSO
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Figure 5.4. Absorbance and Fluorescence of RB GUMBOS in PBS Buffer

Figure 5.5. Absorbance and Fluorescence of R110 GUMBOS in PBS Buffer
5.3.3. Examination of the Cytotoxicity
After detailed characterization, these compounds were then employed in vitro to evaluate
their chemotherapeutic properties. Figures 5.6 and 5.7 are graphical representations of toxicity
studies of RB and R110 based GUMBOS, respectively towards MDA-MB-231 cancer cells.
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Intriguingly, a significant enhancement in toxicity for the GUMBOS was observed as compared
to the parent dye. As shown in the graphs, the respective parent dyes remained relatively non-toxic
until about 200 µM but GUMBOS displayed higher toxicity even at low concentrations. In this
regard, the IC50 values for the parent dyes [RB][Cl] and [R110][Cl] were 291.07 and 791.29 µM
respectively, while RB and R110 based GUMBOS displayed a reduced IC 50 of 80–90 and 100–
200 µM respectively. In order to further understand these variations in IC50, cellular uptake of
these compounds were then examined. As depicted in Figure 5.8, RB and R110 GUMBOS
displayed enhanced cellular uptake as compared to the respective parent dye. This improved
cellular uptake is most likely due to improved hydrophobic interactions of the dye with the
phospholipid bilayer of the cell membrane. These results are consistent with the results from
Belostotsky et al., which demonstrated that variation in hydrophobicity can tune the interaction of
the drug with the cell membrane.6 Furthermore, the nontoxic behavior of [RB][Cl] and [R110][Cl]
at lower concentrations is most likely due to minimal cellular uptake.

Figure 5.6. Toxicity of RB GUMBOS towards MDA-MB-231 cancer cells
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Figure 5.7. Toxicity of R110 GUMBOS towards MDA-MB-231 cancer cells

Figure 5.8. Cellular uptake of RB and R110 GUMBOS
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Since the GUMBOS displayed enhanced therapeutic toxicity towards cancer cells, their
toxicity towards Hs578Bst normal breast cells was also evaluated to further understand their
therapeutic potential. As shown in figure 5.9, R110 and RB GUMBOS displayed slightly toxic
behavior towards normal cells (Figure 5.9). Interestingly, the GUMBOS displayed a significantly
higher IC50 towards cancer cells as compared to normal cells, suggesting partially selective
behavior (Table 5.4). This contradicts the behavior of nanoGUMBOS derived from ester
derivatives reported in Chapter 4 of this dissertation, which displayed completely selective
behavior. In this regard, while the ester derivative GUMBOS formed nanoGUMBOS in aqueous
medium, the RB and R110 GUMBOS are water soluble and do not form nanoGUMBOS. As
indicated earlier, the water solubility of RB and R110 GUMBOS were similar to that of the more
hydrophilic GUMBOS reported in Magut et al.17 Intriguingly, these hydrophilic GUMBOS
displayed toxicity towards normal cells, suggesting that the selective behavior observed for the
nanoGUMBOS derived from the ester rhodamine derivatives is most likely due to nanoparticle
formation.17 This is consistent with the results discussed in Chapter 2 of this dissertation, that the
selectivity of R6G nanoGUMBOS investigated in Magut et al. was dependent upon nanoparticle
formation.
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Figure 5.9. Toxicity of RB GUMBOS toward Hs578Bst normal breast cells

Figure 5.10. Toxicity of R110 GUMBOS toward Hs578Bst normal breast cells
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Table 5.4. IC50 concentrations of RB and R110 GUMBOS towards MDA-MB-231 cancer and
Hs578Bst normal cells
MDA-MB-231
Hs578Bst
Compound
IC50 (μM)
IC50 (μM)
[RB][BETI]

89.56 ± 3.45

540.32 ± 6.29

[RB][TPB]

77.54 ± 5.71

533.77 ± 3.36

[RB][Cl]

291.07 ± 1.23

500.24 ± 5.21

[R110][BETI]

159.51 ± 1.18

843.84 ± 4.93

[R110][TPB]

105.52 ± 3.16

850.22 ± 3.73

[R110][Cl]

791.29 ± 2.79

836.11 ± 5.38

5.3.4. Synthesis and Characterization of Triple GUMBOS
In order to further improve the selective behavior of these hydrophilic GUMBOS, a
secondary cation was added to interact with the carboxylic acid functional group. Since the pKa
of the carboxylic acid group on the rhodamines is around 4, at physiological pH the carboxylic
acid functional group exists in the deprotonated (COO–) form.4, 24 Thus, a secondary cation can be
added to the RB and R110 GUMBOS bearing this carboxylic functional group to enhance
hydrophobicity. Furthermore, this enhanced hydrophobicity could possibly lead to insolubility in
water, enabling nanoGUMBOS formation. This modification of the carboxylic acid structure may
also aid in elimination of poor mitochondrial localization observed for [RB][Cl] and [R110][Cl]
that results from the acid-base properties of the carboxylic acid. Moreover, this modification in the
carboxylic acid structure will ultimately aid in improved toxicity of the GUMBOS, while the
enhanced hydrophobicity may aid in improving the selectivity.
Here, rhodamine 6G chloride and tetrabutylphosphonium bromide were employed as
secondary cations on the [RB][TPB] and [R110][TPB] GUMBOS, and the therapeutic properties
of the new triple GUMBOS were assessed. Rhodamine 6G is a lipophilic cation with known
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anticancer properties; thus, in addition to enhancing the hydrophobicity, it will also aid in
improving the anticancer properties.25 Tetrabutylphosphonium bromide, [P4444][Br], was chosen
due to its minimal systemic toxicity in contrast to other phosphonium compounds.26 [R6G][Cl]
consists of bulky aromatic rings while [P4444][Br] contains aliphatic chains; thus, the effect of the
secondary cation structure on the overall toxicity of the GUMBOS can also be examined. The
formation of triple GUMBOS is presented in the reaction scheme depicted in Figure 5.11. NMR
was then used to confirm addition of the secondary cation (Figure 5.12 and 5.13).
Subsequently, octanol-water partition coefficients were performed for all the triple
GUMBOS to assess their relative hydrophobicity. As shown in table 5.5, the [RB][R6G][TPB]
GUMBOS displayed a greater hydrophobicity than the [RB][P4444][TPB] GUMBOS. A similar
trend was also observed for the R110 based triple GUMBOS such that the [R110][R6G][TPB] was
relatively more hydrophobic than [R110][P4444][TPB]. This behavior can be explained by the
aromatic structure of R6G as compared to the aliphatic structure of P4444. Furthermore, the
hydrophobicity of these triple GUMBOS are substantially increased as compared to that of
[R110][TPB] and [RB][TPB]. In this regard, the triple GUMBOS were found to be insoluble in
water.
Since the GUMBOS displayed insolubility in water, nanoGUMBOS were synthesized
through a reprecipitation method described in the experimental section. Figures 5.14 and 5.15
display the TEM images for all the investigated nanoGUMBOS. Interestingly, fairly spherical
nanoparticles with a size of approximately 100 nm was observed for all the nanoGUMBOS. This
size is similar to the sizes observed in both the R6G based nanoGUMBOS in Magut et al. and the
R123 and SNAFR nanoGUMBOS presented in Chapter 4 of this dissertation.17
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Figure 5.11. Synthesis of rhodamine based triple GUMBOS
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Figure 5.12. NMR spectra of RB0based triple GUMBOS
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Figure 5.13. NMR spectra of R110-based triple GUMBOS
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Table 5.5. Hydrophobicity of RB and R110-based triple GUMBOS
Compound

Log Kow

[RB][R6G][TPB]

1.95 ± 0.11

[R110][R6G][TPB]

1.34 ± 0.24

[RB][P4444][TPB]

1.73 ± 0.29

[R110][P4444][TPB]

1.12 ± 0.15

Figure 5.14. TEM images of RB-based triple GUMBOS

Figure 5.15. TEM images of R110-based triple GUMBOS
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5.3.5. Spectroscopic studies of RB and R110 triple GUMBOS
Absorbance and fluorescence measurements were conducted for all the synthesized
GUMBOS and nanoGUMBOS to examine the effect of the secondary cation on the spectral
properties. Figure 5.16 displays the absorbance and fluorescence spectrum of RB and R110 triple
GUMBOS and their respective parent dyes in DMSO. Interestingly, both the [RB][R6G][TPB]
and [R110][R6G][TPB] displayed absorbance and emission peak maxima respectively at 537 and
575 nm, which is identical to that of [R6G][Cl]. In contrast, [RB][P4444][TPB] and
[R110][P4444][TPB] showed absorbance and emission peaks similar to that of [R110][Cl] and
[RB][Cl] respectively. In this regard, [RB][P4444][TPB] displayed an absorbance and emission of
549 and 571 nm, respectively. [R110][P4444][TPB] displayed an absorbance and emission at 510
and 538 nm, respectively.
Subsequently, fluorescence and absorbance of the nanoGUMBOS in PBS buffer was also
investigated to better understand the optical behavior in a biological environment (Figures 5.17).
In contrast to the absorbance measured in DMSO, the absorbance of [R110][P4444][TPB]
nanoGUMBOS in water was 5 nm blue shifted to 496 nm while the absorbance of
[RB][P4444][TPB] nanoGUMBOS remained at 548 nm. Interestingly, the absorbance shift for
[R110][P4444][TPB] is consistent with [R110][Cl], whereas [RB][P4444][TPB] is 5 nm blue
shifted in comparison to [RB][Cl]. Fluorescence emission of [R110][P4444][TPB] and
[RB][P4444][TPB] in water are observed at 518 nm and 575 nm, respectively, which is consistent
with their respective parent dyes. In contrast to these P4444 triple GUMBOS, a significant change
in peak shape was observed for the [RB][R6G][TPB] and [R110][R6G][TPB] as compared to their
parent dyes. In the case of [RB][R6G][TPB], the absorbance and emission maxima was broadened
to an absorbance maxima of 534 nm and an emission maxima of 557 nm. In this regard, while the
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absorbance maxima was relatively similar to that of [R6G][Cl], the peak was broadened to span
the peak wavelength of both [RB][Cl] and [R6G][Cl]. Similarly, for the [R110][R6G][TPB]
nanoGUMBOS, while the characteristic R110 peak at 496 nm was still observed, a shoulder peak
corresponding to the [R6G][Cl] wavelength at 527 nm was also displayed. Substantial fluorescence
emission is observed from both peaks, indicating that the [R110][R6G][TPB] nanoGUMBOS
displayed spectral properties of both [R110][Cl] and [R6G][Cl]. These results suggest that addition
of the secondary cation can be used to shift the peak wavelength of the GUMBOS.

Figure 5.16. UV-Vis and fluorescence characterization of RB and R110-based triple GUMBOS in
DMSO
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Figure 5.17. UV-Vis and fluorescence characterization of RB and R110-based triple
nanoGUMBOS in water
5.3.6. Examination of selective chemotherapeutic applications of Triple GUMBOS
NanoGUMBOS were then tested in vitro on MDA-MB-231 cancer cells to evaluate their
therapeutic efficacy. Figure 5.18 shows the toxicity of the R110 and RB based nanoGUMBOS,
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respectively and IC50 values are reported in Table 5.6. As seen in Figure 5.18, [RB][R6G][TPB]
nanoGUMBOS displayed higher toxicity than that of the [RB][P4444][TPB] nanoGUMBOS. In
this regard, [RB][P4444][TPB] displayed an IC50 of 25 μM while [RB][R6G][TPB]
nanoGUMBOS displayed an IC50 around 3 μM, indicating almost a 10 fold enhancement in
toxicity for the [R6G][R6G][TPB] nnanoGUMBOS. This improved toxicity can be attributed to
the anticancer properties of the R6G cation.25,
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As shown in Table 5.6, the IC50 value of

[P4444][Br] was larger than 100 µM, indicating minimal to no toxicity towards breast cancer cells.
In contrast, [R6G][Cl] has a IC50 value around 5 μM, thus giving the R6G based triple GUMBOS
a dual anticancer structure from both the RB and R6G cations. A similar trend was also observed
for the R110 based triple nanoGUMBOS. Comparison of the toxicity of these triple GUMBOS to
the respective parent dyes suggests a significant enhancement in toxicity for the triple GUMBOS.
Furthermore, toxicity of the triple nanoGUMBOS was also improved as compared to the
[RB][TPB] and [R110][TPB] GUMBOS.

Figure 5.18. Toxicity of triple GUMBOS towards MDA-MB-231 cancer cells
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Table 5.6. IC50 concentrations of triple GUMBOS towards MDA-MB-231 cancer cells
MDA-MB-231
Compound
IC50 (µM)
[RB][R6G][TPB]

2.54 ± 0.73

[R110][R6G][TPB]

7.12 ± 0.84

[RB][P4444][TPB]

24.46 ± 1.14

[R110][P4444][TPB]

57.22 ± 1.37

[P4444][Br]

≥ 100

[R6G][Cl]

5.27 ± 0.88

Cellular uptake studies were then performed for all the synthesized triple nanoGUMBOS.
Figure 5.19 is a graphical representation of cellular uptake of all the compounds presented in
picomoles internalized after 5 h. incubation of a 12.5 μM nanoGUMBOS solution.
[RB][R6G][TPB] and [R110][R6G][TPB] nanoGUMBOS displayed significantly greater uptake
as compared to [RB][P4444][TPB] and [R110][P4444][TPB]. This further corroborates the
enhanced toxicity observed for the [RB][R6G][TPB] and [R110][R6G][TPB]. Furthermore, all
triple nanoGUMBOS displayed an improved cellular uptake and toxicity as compared to the
respective GUMBOS and parent dyes. This enhanced cellular uptake is most likely attributed to
the modification of the zwitterion structure and formation of nanoGUMBOS. Thus, the
electrostatic repulsion observed between the zwitterion structure of the dye and cell membrane is
minimized.
In order to further corroborate this enhanced toxicity and cellular uptake, fluorescence
microscopy was then employed to examine mitochondrial localization of the dye. Intriguingly, the
triple GUMBOS displayed a substantially improved localization as compared to the parent dye.
Figure 5.20 is a graphical representation of an overlay of fluorescence from mitotracker green
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(green fluorescence) and the compound (red fluorescence). Almost 100% colocalization between
the triple nanoGUMBOS and mitotracker was observed, indicating good mitochondrial
accumulation. In contrast, the parent dye [RB][Cl] only had a 60% colocalization with the
mitotracker, indicating only partial mitochondrial accumulation. These results indicate that in
addition to increased cellular internalization, the improved mitochondrial colocalization also aided
in the improved therapeutic efficacy.

Figure 5.19. Cellular uptake of triple GUMBOS reported as nanomoles internalized
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Figure 5.20. Microscopy image of RB compounds incubated in MDA-MB-231 cancer cells
displaying the merged overlay between the RB dye and mitotracker.
Since the triple nanoGUMBOS displayed improved chemotherapeutic toxicity, it is
essential to investigate their toxicity in breast normal cells to evaluate their selective behavior.
Figure 5.21 displayed the toxicity of RB and R110 based triple nanoGUMBOS in Hs578Bst
normal breast cells. Intriguingly, no toxicity was observed for the nanomaterials under examined
conditions. This suggests that formation of the nanoGUMBOS led to selective toxicity towards
cancer cells with no toxicity towards normal cell under examined conditions, which is similar
behavior to that of previously investigated R6G nanoGUMBOS.
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Figure 5.21. Toxicity of triple GUMBOS towards Hs578Bst normal cells
5.4. CONCLUSIONS
The results reported here demonstrate tunable hydrophobicity, solubility, and photophysical properties of the GUMBOS through counter-ion variation. In this regard, the carboxylic
acid functional groups of the R110 and RB compounds led to the formation of GUMBOS that
were partly water soluble, ultimately resulting in lack of nanoparticle formation. In vitro evaluation
of these compounds suggested that these carboxylic acid derivative rhodamine GUMBOS
displayed non-selective behavior. This is consistent with the non-selective behavior of the more
hydrophilic R6G nanoGUMBOS investigated in Magut et al.17 Intriguingly, addition of a
secondary cation on the carboxylic acid structure led to formation of triple nanoGUMBS that were
found to have selective chemotherapeutic toxicity under examined conditions. This indicates that
the selective chemotherapeutic behavior is most likely dependent upon nanoparticle formation,
similar to the findings reported in Chapter 2 of this dissertation. Furthermore, these triple
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GUMBOS displayed a significantly improved toxicity towards cancer cells in contrast to the
respective GUMBOS and parent dyes, suggesting their great therapeutic potential. Moreover, these
findings indicate that the nanoGUMBOS concept can be used for various cationic dyes to generate
an array of selective chemotherapeutics to combat the problem of systemic toxicity of current
chemotherapeutics.
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CHAPTER 6
CONCLUSIONS AND FUTURE WORK
6.1. CONCLUSIONS
This dissertation discusses the chemotherapeutic potential of rhodamine based GUMBOS
and concludes that the selective chemotherapeutic behavior observed previously in our group with
the R6G nanoGUMBOS is observed for other rhodamine cation structures as well. The studies in
Chapter 2 investigate the mechanism of selective toxicity and in vivo applications of R6G based
nanoGUMBOS. These studies provide insight into a simple technique for development of more
selective chemotherapeutics, and give further understanding to the potential clinical application of
the nanoGUMBOS. As shown in Chapter 3, the toxicity of the nanoGUMBOS can be optimized
by tuning the size of the nanoparticle. Using cyclodextrin to control the size of the nanoparticle
suggested a size dependence on the chemotherapeutic toxicity, which is consistent with literature
findings that suggest 80-100 nm as an optimal size for enhanced efficacy of nanomaterials
employed biomedical applications. Furthermore, studies investigated in Chapters 4 and 5 indicate
a structural dependence on the selective behavior of the examined nanomaterials. In this regard,
while the GUMBOS derived from the zwitterion rhodamines displayed non-selective behavior,
addition of a secondary cation on the carboxylic acid functional group led to selective behavior
under the experimental conditions used in this work. Thus, from these studies, we can conclude
that the GUMBOS concept can be applied to other hydrophobic cationic drugs to minimize their
systemic toxicity.
6.2. FUTURE WORK
While this dissertation primarily focuses GUMBOS derived from rhodamine derivatives
and their selective chemotherapeutic behavior, it would be interesting to examine if a similar
behavior is also observed for other lipophilic cations. Since the rhodamines absorb light in the UV137

Vis range, it would be interesting to investigate this behavior in near infrared (NIR) dyes. NIR
dyes absorb in the NIR region, which is known as the tissue transparent region, enabling use for
both imaging and therapeutic purposes. This can be especially beneficial for fluorescence guided
surgery applications. Furthermore, as the in vivo studies indicated a significant reduction in tumor
volume, thus it would be of interest to examine if enhanced therapeutic efficacy is observed after
addition of targeting ligands such as antibodies overexpressed on the breast cancer cells surface.
Furthermore, for future examinations of the in vivo behavior, pathology studies of an untumored
mouse treated with the nanoGUMBOS can provide further insight to the in vivo selectivity.
Additionally, evaluation in vivo drug halflife within the blood plasma will provide further
knowledge for possible clinical applications of the nanoGUMBOS. For future in vivo studies, use
of the cyclodextrin templating method may also aid in minimizing the agglomeration observed in
the results presented in this dissertation. In addition, the cyclodextrin (CD) templating can be
modified to complex the cyclodextrin with the dye to assess the effect of CD as a drug delivery
agent on the therapeutic properties of the nanoGUMBOS. Lastly, examination of the excretion of
the cyclodextrin templated nanoparticles in contrast to the untemplated nanoparticles can provide
further understanding of pharmacokinetic behavior of these nanomaterials.
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